

Table 1. Five-Year Relative Survival*, All Cancer Sites Combined, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| All Cancer Sites Combined | | | | | | | | | | | | |
|---------------------------|-----------------|-------------------|---------|---------|-----------|-------------------|---------|---------|-----------|-------------------|---------|---------|
| Age group | All Races | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 11,551,970 | 65.9% | 65.9% | 65.9% | 5,974,526 | 65.9% | 65.8% | 65.9% | 5,577,444 | 66.0% | 65.9% | 66.0% |
| Ages <45 | 1,122,627 | 81.3% | 81.2% | 81.4% | 435,225 | 76.6% | 76.5% | 76.7% | 687,402 | 84.3% | 84.2% | 84.4% |
| Ages 45-54 | 1,704,177 | 72.7% | 72.6% | 72.7% | 775,208 | 67.2% | 67.1% | 67.3% | 928,969 | 77.2% | 77.1% | 77.3% |
| Ages 55-64 | 2,795,570 | 69.3% | 69.2% | 69.3% | 1,575,964 | 68.9% | 68.8% | 69.0% | 1,219,606 | 69.8% | 69.7% | 69.8% |
| Ages 65-74 | 2,991,024 | 65.1% | 65.0% | 65.2% | 1,749,593 | 67.7% | 67.6% | 67.8% | 1,241,431 | 61.4% | 61.3% | 61.5% |
| Ages 75+ | 2,938,572 | 52.7% | 52.6% | 52.8% | 1,438,536 | 55.7% | 55.5% | 55.8% | 1,500,036 | 49.9% | 49.8% | 50.0% |
| Ages <65 | 5,622,374 | 72.7% | 72.7% | 72.8% | 2,786,397 | 69.6% | 69.6% | 69.7% | 2,835,977 | 75.8% | 75.7% | 75.9% |
| Ages 65+ | 5,929,596 | 59.1% | 59.0% | 59.2% | 3,188,129 | 62.5% | 62.4% | 62.5% | 2,741,467 | 55.2% | 55.1% | 55.3% |

| All Cancer Sites Combined | | | | | | | | | | | | |
|---------------------------|-----------------|-------------------|---------|---------|-----------|-------------------|---------|---------|-----------|-------------------|---------|---------|
| Age group | White | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 9,711,886 | 66.1% | 66.1% | 66.2% | 5,013,512 | 65.8% | 65.7% | 65.8% | 4,698,374 | 66.5% | 66.5% | 66.6% |
| Ages <45 | 896,724 | 82.8% | 82.7% | 82.9% | 352,743 | 78.3% | 78.1% | 78.4% | 543,981 | 85.7% | 85.6% | 85.8% |
| Ages 45-54 | 1,367,680 | 73.9% | 73.8% | 74.0% | 617,214 | 68.0% | 67.9% | 68.1% | 750,466 | 78.7% | 78.6% | 78.8% |
| Ages 55-64 | 2,300,200 | 69.8% | 69.7% | 69.9% | 1,285,794 | 69.0% | 68.9% | 69.1% | 1,014,406 | 70.8% | 70.7% | 70.9% |
| Ages 65-74 | 2,545,043 | 65.2% | 65.1% | 65.3% | 1,483,133 | 67.4% | 67.3% | 67.5% | 1,061,910 | 62.2% | 62.1% | 62.3% |
| Ages 75+ | 2,602,239 | 53.0% | 52.9% | 53.1% | 1,274,628 | 55.4% | 55.2% | 55.5% | 1,327,611 | 50.7% | 50.5% | 50.8% |
| Ages <65 | 4,564,604 | 73.6% | 73.6% | 73.7% | 2,255,751 | 70.2% | 70.1% | 70.3% | 2,308,853 | 77.0% | 76.9% | 77.0% |
| Ages 65+ | 5,147,282 | 59.2% | 59.1% | 59.2% | 2,757,761 | 62.0% | 61.9% | 62.1% | 2,389,521 | 55.9% | 55.8% | 56.0% |

| All Cancer Sites Combined | | | | | | | | | | | | |
|---------------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Black | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 1,309,965 | 60.6% | 60.5% | 60.7% | 688,168 | 63.0% | 62.9% | 63.2% | 621,797 | 58.0% | 57.9% | 58.2% |
| Ages <45 | 144,763 | 70.3% | 70.0% | 70.5% | 53,166 | 63.6% | 63.1% | 64.0% | 91,597 | 74.2% | 73.9% | 74.5% |
| Ages 45-54 | 244,374 | 63.3% | 63.1% | 63.5% | 120,337 | 60.9% | 60.6% | 61.2% | 124,037 | 65.6% | 65.3% | 66.0% |
| Ages 55-64 | 369,166 | 63.3% | 63.1% | 63.5% | 220,873 | 66.0% | 65.7% | 66.2% | 148,293 | 59.4% | 59.1% | 59.7% |
| Ages 65-74 | 320,185 | 61.0% | 60.8% | 61.3% | 188,862 | 66.8% | 66.5% | 67.1% | 131,323 | 52.9% | 52.5% | 53.2% |
| Ages 75+ | 231,477 | 45.8% | 45.5% | 46.2% | 104,930 | 52.0% | 51.5% | 52.5% | 126,547 | 40.8% | 40.4% | 41.2% |
| Ages <65 | 758,303 | 64.7% | 64.5% | 64.8% | 394,376 | 64.1% | 63.9% | 64.2% | 363,927 | 65.4% | 65.2% | 65.5% |
| Ages 65+ | 551,662 | 54.9% | 54.7% | 55.1% | 293,792 | 61.7% | 61.4% | 62.0% | 257,870 | 47.1% | 46.8% | 47.4% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 2. Five-Year Relative Survival*, Oral Cavity and Pharynx Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Oral Cavity and Pharynx Cancer | | | | | | | | | | | | |
|--------------------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | All Races | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 322,237 | 60.1% | 59.9% | 60.3% | 224,886 | 58.9% | 58.7% | 59.2% | 97,351 | 62.8% | 62.4% | 63.2% |
| Ages <45 | 26,977 | 77.6% | 77.1% | 78.2% | 16,949 | 74.6% | 73.9% | 75.4% | 10,028 | 82.7% | 81.8% | 83.5% |
| Ages 45-54 | 65,701 | 66.1% | 65.7% | 66.6% | 49,485 | 64.7% | 64.2% | 65.2% | 16,216 | 70.5% | 69.7% | 71.3% |
| Ages 55-64 | 92,923 | 61.2% | 60.8% | 61.6% | 70,513 | 59.8% | 59.3% | 60.2% | 22,410 | 65.5% | 64.8% | 66.3% |
| Ages 65-74 | 73,376 | 55.2% | 54.7% | 55.7% | 51,458 | 53.5% | 52.9% | 54.0% | 21,918 | 59.0% | 58.2% | 59.8% |
| Ages 75+ | 66,162 | 48.4% | 47.7% | 49.0% | 38,420 | 47.3% | 46.5% | 48.1% | 27,742 | 49.7% | 48.8% | 50.7% |
| Ages <65 | 184,451 | 65.6% | 65.3% | 65.9% | 136,125 | 63.6% | 63.3% | 64.0% | 48,326 | 71.0% | 70.5% | 71.5% |
| Ages 65+ | 138,809 | 52.1% | 51.7% | 52.4% | 89,455 | 50.9% | 50.4% | 51.4% | 49,354 | 54.0% | 53.4% | 54.6% |

| Oral Cavity and Pharynx Cancer | | | | | | | | | | | | |
|--------------------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | White | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 274,741 | 61.5% | 61.2% | 61.7% | 192,316 | 60.8% | 60.5% | 61.1% | 82,425 | 63.0% | 62.6% | 63.4% |
| Ages <45 | 20,279 | 79.3% | 78.7% | 79.9% | 12,939 | 76.7% | 75.9% | 77.5% | 7,340 | 83.9% | 83.0% | 84.8% |
| Ages 45-54 | 53,839 | 68.9% | 68.5% | 69.4% | 41,061 | 67.8% | 67.3% | 68.3% | 12,778 | 72.5% | 71.6% | 73.4% |
| Ages 55-64 | 78,750 | 63.3% | 62.8% | 63.7% | 60,029 | 62.1% | 61.6% | 62.6% | 18,721 | 66.8% | 66.0% | 67.6% |
| Ages 65-74 | 64,014 | 56.7% | 56.2% | 57.2% | 44,861 | 55.4% | 54.8% | 56.0% | 19,153 | 59.5% | 58.6% | 60.4% |
| Ages 75+ | 60,423 | 48.9% | 48.3% | 49.6% | 35,130 | 48.2% | 47.3% | 49.0% | 25,293 | 49.9% | 48.9% | 50.9% |
| Ages <65 | 151,899 | 67.7% | 67.4% | 67.9% | 113,334 | 66.1% | 65.8% | 66.4% | 38,565 | 72.2% | 71.7% | 72.7% |
| Ages 65+ | 123,762 | 53.1% | 52.7% | 53.5% | 79,600 | 52.4% | 51.9% | 52.9% | 44,162 | 54.3% | 53.6% | 54.9% |

| Oral Cavity and Pharynx Cancer | | | | | | | | | | | | |
|--------------------------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Black | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 32,912 | 44.2% | 43.5% | 44.8% | 23,049 | 39.7% | 38.9% | 40.4% | 9,863 | 54.6% | 53.4% | 55.8% |
| Ages <45 | 3,793 | 65.0% | 63.3% | 66.7% | 2,213 | 57.8% | 55.5% | 60.1% | 1,580 | 75.1% | 72.6% | 77.3% |
| Ages 45-54 | 8,485 | 45.0% | 43.8% | 46.2% | 6,097 | 41.1% | 39.6% | 42.5% | 2,388 | 55.2% | 52.9% | 57.4% |
| Ages 55-64 | 10,497 | 42.4% | 41.3% | 43.6% | 7,899 | 39.3% | 37.9% | 40.6% | 2,598 | 52.1% | 49.7% | 54.3% |
| Ages 65-74 | 6,705 | 37.4% | 35.9% | 38.9% | 4,866 | 33.2% | 31.5% | 35.0% | 1,839 | 48.0% | 45.1% | 50.8% |
| Ages 75+ | 3,677 | 34.9% | 32.5% | 37.3% | 2,144 | 29.7% | 26.7% | 32.7% | 1,533 | 41.8% | 38.1% | 45.5% |
| Ages <65 | 22,643 | 47.4% | 46.7% | 48.2% | 16,119 | 42.7% | 41.8% | 43.6% | 6,524 | 59.1% | 57.8% | 60.5% |
| Ages 65+ | 10,347 | 36.4% | 35.1% | 37.6% | 6,989 | 32.1% | 30.6% | 33.6% | 3,358 | 45.1% | 42.8% | 47.4% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 3. Five-Year Relative Survival*, Esophageal Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Esophageal Cancer | | | | | | | | | | | |
|-------------------|-----------------|-------------------|---------|---------|-----------|-------------------|---------|---------|--------|-------------------|---------|
| Age group | Male and female | | | | All Races | | | | | | |
| | | | | | Male | | | | Female | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI |
| All Ages | 143,690 | 18.2% | 18.0% | 18.5% | 111,792 | 18.1% | 17.8% | 18.4% | 31,898 | 18.7% | 18.2% |
| Ages <45 | 3,863 | 22.4% | 21.0% | 23.9% | 3,132 | 21.2% | 19.7% | 22.8% | 731 | 27.5% | 24.1% |
| Ages 45-54 | 17,303 | 21.0% | 20.3% | 21.6% | 14,315 | 20.3% | 19.6% | 21.0% | 2,988 | 24.2% | 22.5% |
| Ages 55-64 | 37,503 | 20.1% | 19.6% | 20.6% | 31,073 | 19.7% | 19.2% | 20.2% | 6,430 | 22.1% | 21.0% |
| Ages 65-74 | 41,811 | 19.6% | 19.1% | 20.0% | 33,086 | 19.1% | 18.6% | 19.6% | 8,725 | 21.2% | 20.2% |
| Ages 75+ | 43,320 | 13.5% | 13.0% | 13.9% | 30,270 | 13.6% | 13.0% | 14.1% | 13,050 | 13.3% | 12.5% |
| Ages <65 | 58,648 | 20.5% | 20.2% | 20.9% | 48,504 | 20.0% | 19.6% | 20.4% | 10,144 | 23.1% | 22.2% |
| Ages 65+ | 85,081 | 16.6% | 16.2% | 16.9% | 63,318 | 16.5% | 16.2% | 16.9% | 21,763 | 16.6% | 16.0% |

| Esophageal Cancer | | | | | | | | | | | |
|-------------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|
| Age group | Male and female | | | | White | | | | | | |
| | | | | | Male | | | | Female | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI |
| All Ages | 123,087 | 18.9% | 18.7% | 19.2% | 97,169 | 18.8% | 18.5% | 19.1% | 25,918 | 19.4% | 18.8% |
| Ages <45 | 3,181 | 23.0% | 21.4% | 24.6% | 2,668 | 21.5% | 19.8% | 23.3% | 513 | 31.0% | 26.6% |
| Ages 45-54 | 13,935 | 22.5% | 21.7% | 23.3% | 11,886 | 21.7% | 20.9% | 22.5% | 2,049 | 27.3% | 25.1% |
| Ages 55-64 | 30,957 | 21.3% | 20.8% | 21.9% | 26,148 | 20.8% | 20.3% | 21.4% | 4,809 | 23.9% | 22.5% |
| Ages 65-74 | 36,127 | 20.3% | 19.8% | 20.8% | 28,999 | 19.9% | 19.3% | 20.5% | 7,128 | 21.9% | 20.8% |
| Ages 75+ | 38,983 | 13.7% | 13.2% | 14.2% | 27,545 | 13.8% | 13.2% | 14.4% | 11,438 | 13.4% | 12.6% |
| Ages <65 | 48,057 | 21.8% | 21.4% | 22.2% | 40,689 | 21.2% | 20.7% | 21.6% | 7,368 | 25.3% | 24.2% |
| Ages 65+ | 75,063 | 17.0% | 16.6% | 17.3% | 56,507 | 17.0% | 16.6% | 17.4% | 18,556 | 16.8% | 16.2% |

| Esophageal Cancer | | | | | | | | | | | |
|-------------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|
| Age group | Male and female | | | | Black | | | | | | |
| | | | | | Male | | | | Female | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI |
| All Ages | 16,903 | 11.9% | 11.3% | 12.5% | 11,941 | 11.1% | 10.4% | 11.8% | 4,962 | 13.8% | 12.6% |
| Ages <45 | 540 | 15.7% | 12.5% | 19.2% | 355 | 14.8% | 11.0% | 19.1% | 185 | 17.3% | 11.9% |
| Ages 45-54 | 2,905 | 12.5% | 11.2% | 13.9% | 2,060 | 11.2% | 9.7% | 12.8% | 845 | 15.7% | 13.1% |
| Ages 55-64 | 5,568 | 12.1% | 11.1% | 13.1% | 4,170 | 11.4% | 10.3% | 12.6% | 1,398 | 14.2% | 12.1% |
| Ages 65-74 | 4,633 | 12.2% | 11.1% | 13.4% | 3,339 | 11.1% | 9.8% | 12.5% | 1,294 | 15.1% | 12.8% |
| Ages 75+ | 3,269 | 9.8% | 8.4% | 11.4% | 2,023 | 9.7% | 7.9% | 11.7% | 1,246 | 10.0% | 7.9% |
| Ages <65 | 9,009 | 12.5% | 11.7% | 13.3% | 6,583 | 11.5% | 10.7% | 12.4% | 2,426 | 15.0% | 13.4% |
| Ages 65+ | 7,899 | 11.2% | 10.3% | 12.1% | 5,361 | 10.6% | 9.5% | 11.7% | 2,538 | 12.6% | 11.0% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 4. Five-Year Relative Survival*, Stomach Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries†, 2001-2013.

| Stomach Cancer | | | | | | | | | | | | |
|----------------|-----------------|-------------------|---------|---------|-----------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | All Races | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 202,224 | 29.5% | 29.2% | 29.7% | 124,186 | 27.2% | 26.9% | 27.5% | 78,038 | 33.0% | 32.6% | 33.4% |
| Ages <45 | 11,862 | 37.3% | 36.3% | 38.2% | 6,382 | 33.4% | 32.2% | 34.7% | 5,480 | 41.8% | 40.4% | 43.2% |
| Ages 45-54 | 23,450 | 34.5% | 33.8% | 35.2% | 14,911 | 31.2% | 30.3% | 32.0% | 8,539 | 40.3% | 39.2% | 41.5% |
| Ages 55-64 | 39,649 | 32.4% | 31.8% | 32.9% | 27,040 | 29.7% | 29.1% | 30.4% | 12,609 | 38.1% | 37.1% | 39.1% |
| Ages 65-74 | 51,898 | 31.3% | 30.8% | 31.8% | 34,167 | 28.6% | 28.0% | 29.2% | 17,731 | 36.3% | 35.5% | 37.2% |
| Ages 75+ | 75,601 | 23.6% | 23.1% | 24.0% | 41,826 | 21.7% | 21.1% | 22.3% | 33,775 | 25.8% | 25.1% | 26.4% |
| Ages <65 | 74,887 | 33.8% | 33.4% | 34.2% | 48,290 | 30.7% | 30.2% | 31.1% | 26,597 | 39.6% | 38.9% | 40.2% |
| Ages 65+ | 127,420 | 26.8% | 26.5% | 27.1% | 75,946 | 24.9% | 24.5% | 25.3% | 51,474 | 29.5% | 29.0% | 30.0% |

| Stomach Cancer | | | | | | | | | | | | |
|----------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | White | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 152,856 | 28.2% | 27.9% | 28.5% | 95,938 | 26.0% | 25.7% | 26.4% | 56,918 | 31.9% | 31.4% | 32.4% |
| Ages <45 | 8,091 | 36.6% | 35.5% | 37.8% | 4,490 | 32.1% | 30.6% | 33.6% | 3,601 | 42.4% | 40.6% | 44.1% |
| Ages 45-54 | 16,403 | 32.8% | 32.0% | 33.6% | 10,685 | 29.3% | 28.3% | 30.3% | 5,718 | 39.4% | 37.9% | 40.8% |
| Ages 55-64 | 29,073 | 30.9% | 30.2% | 31.5% | 20,316 | 28.2% | 27.5% | 28.9% | 8,757 | 36.9% | 35.8% | 38.1% |
| Ages 65-74 | 39,386 | 30.1% | 29.5% | 30.7% | 26,540 | 27.7% | 27.0% | 28.3% | 12,846 | 35.1% | 34.1% | 36.1% |
| Ages 75+ | 60,071 | 23.1% | 22.6% | 23.6% | 34,007 | 21.3% | 20.7% | 22.0% | 26,064 | 25.2% | 24.4% | 25.9% |
| Ages <65 | 53,519 | 32.3% | 31.9% | 32.8% | 35,461 | 29.1% | 28.5% | 29.6% | 18,058 | 38.8% | 38.0% | 39.6% |
| Ages 65+ | 99,400 | 25.9% | 25.6% | 26.3% | 60,514 | 24.2% | 23.7% | 24.7% | 38,886 | 28.5% | 27.9% | 29.1% |

| Stomach Cancer | | | | | | | | | | | | |
|----------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | Black | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 32,922 | 29.4% | 28.8% | 30.0% | 18,713 | 26.3% | 25.5% | 27.1% | 14,209 | 33.5% | 32.6% | 34.5% |
| Ages <45 | 2,295 | 33.7% | 31.6% | 35.9% | 1,174 | 30.5% | 27.6% | 33.4% | 1,121 | 37.1% | 34.0% | 40.2% |
| Ages 45-54 | 4,721 | 34.9% | 33.4% | 36.4% | 2,893 | 30.6% | 28.7% | 32.5% | 1,828 | 41.7% | 39.2% | 44.2% |
| Ages 55-64 | 7,211 | 32.2% | 30.9% | 33.5% | 4,619 | 28.7% | 27.1% | 30.3% | 2,592 | 38.4% | 36.2% | 40.6% |
| Ages 65-74 | 8,332 | 30.8% | 29.6% | 32.1% | 5,088 | 27.0% | 25.4% | 28.5% | 3,244 | 36.8% | 34.8% | 38.8% |
| Ages 75+ | 10,409 | 22.5% | 21.3% | 23.7% | 4,964 | 19.2% | 17.5% | 20.9% | 5,445 | 25.3% | 23.7% | 27.0% |
| Ages <65 | 14,210 | 33.3% | 32.4% | 34.2% | 8,678 | 29.6% | 28.4% | 30.7% | 5,532 | 39.2% | 37.8% | 40.7% |
| Ages 65+ | 18,727 | 26.3% | 25.5% | 27.2% | 10,045 | 23.3% | 22.2% | 24.5% | 8,682 | 29.7% | 28.5% | 31.0% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

†Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 5. Five-Year Relative Survival*, Colon and Rectum Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Colon and Rectum Cancer | | | | | | | | | | | | |
|-------------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|---------|-------------------|---------|---------|
| All Races | | | | | | | | | | | | |
| Age group | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 1,314,149 | 63.8% | 63.7% | 63.9% | 670,470 | 63.3% | 63.1% | 63.5% | 643,679 | 64.3% | 64.2% | 64.5% |
| Ages <45 | 65,180 | 68.6% | 68.1% | 69.0% | 33,460 | 66.9% | 66.3% | 67.4% | 31,720 | 70.3% | 69.7% | 70.9% |
| Ages 45-54 | 166,349 | 70.0% | 69.7% | 70.2% | 90,367 | 68.3% | 68.0% | 68.7% | 75,982 | 71.9% | 71.5% | 72.3% |
| Ages 55-64 | 262,090 | 67.5% | 67.3% | 67.7% | 150,193 | 66.6% | 66.3% | 66.9% | 111,897 | 68.8% | 68.5% | 69.1% |
| Ages 65-74 | 332,102 | 65.6% | 65.3% | 65.8% | 182,641 | 64.7% | 64.4% | 64.9% | 149,461 | 66.6% | 66.3% | 66.9% |
| Ages 75+ | 493,026 | 57.8% | 57.6% | 58.1% | 216,442 | 57.0% | 56.6% | 57.3% | 276,584 | 58.4% | 58.1% | 58.7% |
| Ages <65 | 492,507 | 68.5% | 68.4% | 68.7% | 273,348 | 67.2% | 67.0% | 67.4% | 219,159 | 70.1% | 69.9% | 70.3% |
| Ages 65+ | 823,020 | 61.0% | 60.8% | 61.1% | 397,961 | 60.6% | 60.3% | 60.8% | 425,059 | 61.3% | 61.1% | 61.6% |

| Colon and Rectum Cancer | | | | | | | | | | | | |
|-------------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|---------|-------------------|---------|---------|
| White | | | | | | | | | | | | |
| Age group | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 1,100,836 | 64.3% | 64.2% | 64.4% | 565,332 | 63.8% | 63.7% | 64.0% | 535,504 | 64.8% | 64.6% | 65.0% |
| Ages <45 | 50,078 | 69.6% | 69.2% | 70.1% | 26,062 | 67.7% | 67.0% | 68.3% | 24,016 | 71.7% | 71.1% | 72.4% |
| Ages 45-54 | 127,903 | 70.8% | 70.5% | 71.1% | 71,102 | 69.2% | 68.8% | 69.6% | 56,801 | 72.7% | 72.3% | 73.1% |
| Ages 55-64 | 209,232 | 68.1% | 67.9% | 68.4% | 121,918 | 67.2% | 66.9% | 67.5% | 87,314 | 69.5% | 69.1% | 69.8% |
| Ages 65-74 | 279,021 | 66.2% | 65.9% | 66.4% | 155,097 | 65.3% | 65.0% | 65.6% | 123,924 | 67.2% | 66.9% | 67.5% |
| Ages 75+ | 438,471 | 58.7% | 58.4% | 58.9% | 193,367 | 57.8% | 57.4% | 58.1% | 245,104 | 59.3% | 59.0% | 59.7% |
| Ages <65 | 386,338 | 69.2% | 69.1% | 69.4% | 218,562 | 67.9% | 67.7% | 68.2% | 167,776 | 70.9% | 70.6% | 71.1% |
| Ages 65+ | 715,639 | 61.6% | 61.4% | 61.8% | 347,470 | 61.2% | 60.9% | 61.4% | 368,169 | 62.0% | 61.8% | 62.2% |

| Colon and Rectum Cancer | | | | | | | | | | | | |
|-------------------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Black | | | | | | | | | | | | |
| Age group | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 157,813 | 57.8% | 57.5% | 58.2% | 76,280 | 56.3% | 55.8% | 56.8% | 81,533 | 59.3% | 58.8% | 59.7% |
| Ages <45 | 10,475 | 61.2% | 60.2% | 62.3% | 5,037 | 59.0% | 57.4% | 60.5% | 5,438 | 63.3% | 61.8% | 64.7% |
| Ages 45-54 | 28,339 | 63.4% | 62.8% | 64.1% | 14,003 | 60.2% | 59.2% | 61.1% | 14,336 | 66.6% | 65.6% | 67.4% |
| Ages 55-64 | 39,782 | 61.6% | 61.0% | 62.2% | 21,027 | 59.8% | 58.9% | 60.6% | 18,755 | 63.6% | 62.8% | 64.5% |
| Ages 65-74 | 39,313 | 58.7% | 58.0% | 59.3% | 19,960 | 56.6% | 55.6% | 57.5% | 19,353 | 60.7% | 59.8% | 61.6% |
| Ages 75+ | 40,465 | 48.0% | 47.2% | 48.8% | 16,576 | 46.8% | 45.5% | 48.0% | 23,889 | 48.8% | 47.8% | 49.8% |
| Ages <65 | 78,410 | 62.3% | 61.8% | 62.7% | 39,947 | 59.9% | 59.3% | 60.4% | 38,463 | 64.7% | 64.1% | 65.2% |
| Ages 65+ | 79,594 | 53.4% | 52.9% | 53.9% | 36,442 | 52.3% | 51.5% | 53.0% | 43,152 | 54.2% | 53.6% | 54.9% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 6. Five-Year Relative Survival*, Pancreatic Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Pancreatic Cancer | | | | | | | | | | | | |
|-------------------|-----------------|-------------------|---------|---------|-----------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Male and female | | | | All Races | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 345,608 | 8.5% | 8.3% | 8.6% | 173,791 | 8.3% | 8.2% | 8.5% | 171,817 | 8.6% | 8.4% | 8.7% |
| Ages <45 | 9,257 | 30.0% | 29.0% | 31.1% | 4,986 | 24.5% | 23.2% | 25.9% | 4,271 | 36.5% | 34.9% | 38.1% |
| Ages 45-54 | 33,050 | 13.7% | 13.3% | 14.1% | 19,449 | 12.3% | 11.8% | 12.8% | 13,601 | 15.7% | 15.0% | 16.4% |
| Ages 55-64 | 72,632 | 9.9% | 9.6% | 10.1% | 41,692 | 9.0% | 8.7% | 9.3% | 30,940 | 11.0% | 10.6% | 11.5% |
| Ages 65-74 | 95,300 | 8.0% | 7.8% | 8.2% | 50,499 | 7.9% | 7.6% | 8.2% | 44,801 | 8.1% | 7.8% | 8.4% |
| Ages 75+ | 135,422 | 4.9% | 4.8% | 5.1% | 57,195 | 5.2% | 4.9% | 5.4% | 78,227 | 4.8% | 4.5% | 5.0% |
| Ages <65 | 114,917 | 12.7% | 12.5% | 12.9% | 66,113 | 11.2% | 10.9% | 11.5% | 48,804 | 14.7% | 14.3% | 15.0% |
| Ages 65+ | 230,709 | 6.2% | 6.1% | 6.4% | 107,689 | 6.5% | 6.3% | 6.7% | 123,020 | 6.0% | 5.8% | 6.2% |

| Pancreatic Cancer | | | | | | | | | | | | |
|-------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Male and female | | | | White | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 290,573 | 8.2% | 8.1% | 8.3% | 148,067 | 8.2% | 8.0% | 8.3% | 142,506 | 8.2% | 8.0% | 8.4% |
| Ages <45 | 7,046 | 29.3% | 28.1% | 30.5% | 3,888 | 24.4% | 22.9% | 25.9% | 3,158 | 35.4% | 33.6% | 37.3% |
| Ages 45-54 | 25,788 | 13.6% | 13.1% | 14.1% | 15,410 | 12.3% | 11.7% | 12.9% | 10,378 | 15.6% | 14.8% | 16.4% |
| Ages 55-64 | 59,026 | 9.7% | 9.5% | 10.0% | 34,316 | 9.0% | 8.7% | 9.4% | 24,710 | 10.7% | 10.3% | 11.2% |
| Ages 65-74 | 80,228 | 7.9% | 7.7% | 8.2% | 43,406 | 7.8% | 7.5% | 8.2% | 36,822 | 8.0% | 7.7% | 8.4% |
| Ages 75+ | 118,527 | 4.8% | 4.7% | 5.0% | 51,070 | 5.0% | 4.8% | 5.3% | 67,457 | 4.7% | 4.4% | 4.9% |
| Ages <65 | 91,843 | 12.4% | 12.2% | 12.7% | 53,604 | 11.1% | 10.8% | 11.5% | 38,239 | 14.2% | 13.8% | 14.6% |
| Ages 65+ | 198,746 | 6.1% | 6.0% | 6.2% | 94,473 | 6.4% | 6.1% | 6.6% | 104,273 | 5.9% | 5.7% | 6.1% |

| Pancreatic Cancer | | | | | | | | | | | | |
|-------------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | Black | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 43,074 | 8.8% | 8.5% | 9.1% | 19,854 | 8.1% | 7.6% | 8.6% | 23,220 | 9.4% | 8.9% | 9.8% |
| Ages <45 | 1,626 | 30.7% | 28.3% | 33.2% | 780 | 22.2% | 19.1% | 25.6% | 846 | 38.5% | 34.9% | 42.1% |
| Ages 45-54 | 5,947 | 12.3% | 11.3% | 13.3% | 3,292 | 10.6% | 9.4% | 11.9% | 2,655 | 14.3% | 12.8% | 15.9% |
| Ages 55-64 | 10,983 | 9.1% | 8.4% | 9.8% | 5,962 | 7.7% | 6.9% | 8.6% | 5,021 | 10.7% | 9.7% | 11.8% |
| Ages 65-74 | 11,789 | 7.4% | 6.8% | 8.1% | 5,483 | 7.0% | 6.2% | 7.9% | 6,306 | 7.8% | 7.0% | 8.7% |
| Ages 75+ | 12,737 | 4.9% | 4.4% | 5.5% | 4,343 | 5.4% | 4.5% | 6.3% | 8,394 | 4.7% | 4.1% | 5.4% |
| Ages <65 | 18,552 | 12.1% | 11.6% | 12.7% | 10,031 | 9.9% | 9.2% | 10.6% | 8,521 | 14.8% | 13.9% | 15.7% |
| Ages 65+ | 24,524 | 6.1% | 5.7% | 6.5% | 9,824 | 6.3% | 5.6% | 6.9% | 14,700 | 6.1% | 5.6% | 6.6% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 7. Five-Year Relative Survival*, Laryngeal Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Laryngeal Cancer | | | | | | | | | | | | |
|------------------|-----------------|-------------------|---------|---------|-----------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | All Races | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 116,059 | 59.5% | 59.1% | 59.8% | 92,413 | 60.2% | 59.8% | 60.6% | 23,646 | 56.5% | 55.7% | 57.3% |
| Ages <45 | 3,905 | 71.2% | 69.6% | 72.7% | 2,739 | 69.7% | 67.7% | 71.5% | 1,166 | 74.7% | 71.8% | 77.3% |
| Ages 45-54 | 18,860 | 62.6% | 61.8% | 63.4% | 14,657 | 62.3% | 61.4% | 63.2% | 4,203 | 63.7% | 62.0% | 65.4% |
| Ages 55-64 | 35,162 | 59.9% | 59.3% | 60.5% | 28,224 | 59.9% | 59.2% | 60.6% | 6,938 | 59.8% | 58.4% | 61.2% |
| Ages 65-74 | 33,771 | 58.2% | 57.6% | 58.9% | 27,127 | 59.9% | 59.1% | 60.7% | 6,644 | 51.7% | 50.2% | 53.1% |
| Ages 75+ | 24,635 | 55.7% | 54.7% | 56.7% | 19,908 | 58.1% | 56.9% | 59.3% | 4,727 | 46.2% | 44.1% | 48.3% |
| Ages <65 | 57,843 | 61.6% | 61.1% | 62.1% | 45,550 | 61.3% | 60.8% | 61.9% | 12,293 | 62.7% | 61.7% | 63.7% |
| Ages 65+ | 58,314 | 57.1% | 56.6% | 57.7% | 46,952 | 59.1% | 58.4% | 59.7% | 11,362 | 49.5% | 48.2% | 50.7% |

| Laryngeal Cancer | | | | | | | | | | | | |
|------------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | White | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 96,447 | 60.6% | 60.2% | 61.0% | 76,660 | 61.5% | 61.0% | 61.9% | 19,787 | 57.3% | 56.4% | 58.1% |
| Ages <45 | 3,169 | 74.0% | 72.3% | 75.6% | 2,209 | 72.5% | 70.4% | 74.5% | 960 | 77.5% | 74.4% | 80.2% |
| Ages 45-54 | 14,927 | 64.7% | 63.9% | 65.6% | 11,584 | 64.3% | 63.2% | 65.2% | 3,343 | 66.4% | 64.6% | 68.2% |
| Ages 55-64 | 28,439 | 61.5% | 60.8% | 62.2% | 22,750 | 61.7% | 60.9% | 62.5% | 5,689 | 60.6% | 59.1% | 62.1% |
| Ages 65-74 | 28,443 | 58.9% | 58.1% | 59.6% | 22,778 | 60.6% | 59.8% | 61.5% | 5,665 | 52.0% | 50.4% | 53.6% |
| Ages 75+ | 21,707 | 56.3% | 55.2% | 57.4% | 17,548 | 58.8% | 57.5% | 60.0% | 4,159 | 46.4% | 44.2% | 48.6% |
| Ages <65 | 46,468 | 63.5% | 63.0% | 64.0% | 36,488 | 63.2% | 62.7% | 63.8% | 9,980 | 64.3% | 63.2% | 65.4% |
| Ages 65+ | 50,067 | 57.7% | 57.1% | 58.3% | 40,252 | 59.8% | 59.0% | 60.5% | 9,815 | 49.7% | 48.4% | 51.0% |

| Laryngeal Cancer | | | | | | | | | | | | |
|------------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | Black | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 17,093 | 51.5% | 50.5% | 52.4% | 13,645 | 51.6% | 50.5% | 52.7% | 3,448 | 50.9% | 48.9% | 52.9% |
| Ages <45 | 634 | 54.4% | 50.0% | 58.6% | 460 | 53.8% | 48.6% | 58.6% | 174 | 56.2% | 47.7% | 63.8% |
| Ages 45-54 | 3,489 | 52.6% | 50.7% | 54.5% | 2,704 | 52.8% | 50.6% | 54.9% | 785 | 52.0% | 47.9% | 55.9% |
| Ages 55-64 | 5,997 | 50.7% | 49.1% | 52.2% | 4,872 | 49.9% | 48.1% | 51.6% | 1,125 | 54.3% | 50.7% | 57.7% |
| Ages 65-74 | 4,606 | 52.2% | 50.2% | 54.1% | 3,728 | 53.0% | 50.8% | 55.2% | 878 | 48.6% | 44.3% | 52.7% |
| Ages 75+ | 2,401 | 49.3% | 46.0% | 52.6% | 1,912 | 50.9% | 47.0% | 54.6% | 489 | 43.5% | 37.1% | 49.8% |
| Ages <65 | 10,104 | 51.7% | 50.5% | 52.9% | 8,022 | 51.2% | 49.9% | 52.5% | 2,082 | 53.6% | 51.0% | 56.0% |
| Ages 65+ | 6,999 | 51.2% | 49.5% | 52.8% | 5,632 | 52.3% | 50.4% | 54.2% | 1,367 | 46.7% | 43.2% | 50.2% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 8. Five-Year Relative Survival*, Liver Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries†, 2001-2013.

| Liver Cancer | | | | | | | | | | | | |
|--------------|-----------------|-------------------|---------|---------|-----------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | All Races | | | | Female | | | |
| | | | | | Male | | | | | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 191,529 | 17.3% | 17.1% | 17.5% | 136,932 | 16.8% | 16.6% | 17.0% | 54,597 | 18.5% | 18.1% | 18.9% |
| Ages <45 | 8,732 | 36.7% | 35.6% | 37.8% | 5,851 | 33.7% | 32.4% | 35.0% | 2,881 | 42.9% | 40.9% | 44.9% |
| Ages 45-54 | 32,892 | 20.4% | 19.9% | 20.9% | 26,588 | 19.1% | 18.6% | 19.6% | 6,304 | 25.8% | 24.6% | 27.1% |
| Ages 55-64 | 58,723 | 19.6% | 19.2% | 20.0% | 46,375 | 18.4% | 17.9% | 18.8% | 12,348 | 23.9% | 23.0% | 24.8% |
| Ages 65-74 | 45,833 | 15.1% | 14.7% | 15.5% | 31,650 | 14.3% | 13.8% | 14.8% | 14,183 | 16.9% | 16.2% | 17.7% |
| Ages 75+ | 45,486 | 9.2% | 8.8% | 9.5% | 26,565 | 9.2% | 8.7% | 9.8% | 18,921 | 9.0% | 8.4% | 9.6% |
| Ages <65 | 100,297 | 21.5% | 21.2% | 21.8% | 78,775 | 20.0% | 19.6% | 20.3% | 21,522 | 27.2% | 26.5% | 27.9% |
| Ages 65+ | 91,285 | 12.2% | 11.9% | 12.5% | 58,194 | 12.1% | 11.7% | 12.4% | 33,091 | 12.5% | 12.0% | 13.0% |

| Liver Cancer | | | | | | | | | | | | |
|--------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | White | | | | Female | | | |
| | | | | | Male | | | | | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 143,814 | 16.4% | 16.2% | 16.7% | 102,557 | 16.0% | 15.7% | 16.3% | 41,257 | 17.5% | 17.0% | 17.9% |
| Ages <45 | 5,487 | 38.9% | 37.5% | 40.3% | 3,513 | 35.3% | 33.6% | 37.0% | 1,974 | 45.3% | 42.9% | 47.8% |
| Ages 45-54 | 23,474 | 20.6% | 20.0% | 21.2% | 19,089 | 19.4% | 18.8% | 20.0% | 4,385 | 26.0% | 24.5% | 27.5% |
| Ages 55-64 | 41,904 | 19.4% | 18.9% | 19.9% | 33,098 | 18.2% | 17.7% | 18.8% | 8,806 | 23.6% | 22.5% | 24.7% |
| Ages 65-74 | 35,163 | 13.7% | 13.2% | 14.2% | 24,482 | 13.0% | 12.4% | 13.5% | 10,681 | 15.3% | 14.5% | 16.2% |
| Ages 75+ | 37,871 | 8.4% | 8.0% | 8.8% | 22,432 | 8.4% | 7.8% | 9.0% | 15,439 | 8.4% | 7.7% | 9.0% |
| Ages <65 | 70,837 | 21.5% | 21.2% | 21.9% | 55,679 | 19.9% | 19.5% | 20.3% | 15,158 | 27.3% | 26.5% | 28.1% |
| Ages 65+ | 73,009 | 11.0% | 10.7% | 11.3% | 46,899 | 10.9% | 10.5% | 11.3% | 26,110 | 11.3% | 10.8% | 11.8% |

| Liver Cancer | | | | | | | | | | | | |
|--------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | Black | | | | Female | | | |
| | | | | | Male | | | | | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 28,085 | 14.6% | 14.1% | 15.1% | 20,531 | 13.2% | 12.6% | 13.8% | 7,554 | 18.4% | 17.3% | 19.5% |
| Ages <45 | 1,665 | 27.3% | 24.9% | 29.6% | 1,136 | 24.3% | 21.6% | 27.0% | 529 | 33.8% | 29.3% | 38.3% |
| Ages 45-54 | 5,981 | 14.0% | 13.0% | 15.0% | 4,681 | 12.2% | 11.1% | 13.3% | 1,300 | 20.7% | 18.2% | 23.2% |
| Ages 55-64 | 11,407 | 14.7% | 13.9% | 15.6% | 9,101 | 13.3% | 12.4% | 14.3% | 2,306 | 20.1% | 18.0% | 22.3% |
| Ages 65-74 | 5,504 | 12.8% | 11.6% | 14.1% | 3,760 | 10.6% | 9.2% | 12.1% | 1,744 | 16.9% | 14.7% | 19.3% |
| Ages 75+ | 3,554 | 10.1% | 8.7% | 11.7% | 1,874 | 10.6% | 8.6% | 12.8% | 1,680 | 9.6% | 7.7% | 11.8% |
| Ages <65 | 19,039 | 15.8% | 15.2% | 16.5% | 14,907 | 14.0% | 13.4% | 14.8% | 4,132 | 22.3% | 20.8% | 23.8% |
| Ages 65+ | 9,056 | 11.8% | 10.8% | 12.7% | 5,632 | 10.6% | 9.5% | 11.9% | 3,424 | 13.4% | 11.9% | 15.0% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

†Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 9. Five-Year Relative Survival*, Lung and Bronchus Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Lung and Bronchus Cancer | | | | | | | | | | | | |
|--------------------------|-----------------|-------------------|---------|---------|------------------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Male and female | | | | <u>All Races</u> | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 1,872,295 | 18.7% | 18.6% | 18.8% | 1,010,725 | 15.9% | 15.8% | 16.0% | 861,570 | 22.0% | 21.9% | 22.1% |
| Ages <45 | 34,907 | 28.9% | 28.4% | 29.4% | 16,799 | 25.1% | 24.4% | 25.8% | 18,108 | 32.4% | 31.7% | 33.2% |
| Ages 45-54 | 170,679 | 21.9% | 21.7% | 22.1% | 89,890 | 17.8% | 17.5% | 18.0% | 80,789 | 26.6% | 26.2% | 26.9% |
| Ages 55-64 | 411,654 | 20.8% | 20.7% | 21.0% | 229,945 | 17.4% | 17.2% | 17.5% | 181,709 | 25.2% | 25.0% | 25.5% |
| Ages 65-74 | 615,319 | 19.8% | 19.6% | 19.9% | 338,324 | 16.9% | 16.7% | 17.0% | 276,995 | 23.3% | 23.1% | 23.5% |
| Ages 75+ | 649,996 | 14.7% | 14.6% | 14.8% | 340,552 | 12.8% | 12.6% | 12.9% | 309,444 | 16.7% | 16.6% | 16.9% |
| Ages <65 | 615,585 | 21.6% | 21.5% | 21.7% | 335,901 | 17.9% | 17.7% | 18.0% | 279,684 | 26.1% | 25.9% | 26.3% |
| Ages 65+ | 1,260,722 | 17.2% | 17.1% | 17.3% | 676,687 | 14.9% | 14.7% | 15.0% | 584,035 | 19.9% | 19.8% | 20.0% |

| Lung and Bronchus Cancer | | | | | | | | | | | | |
|--------------------------|-----------------|-------------------|---------|---------|--------------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Male and female | | | | <u>White</u> | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 1,620,929 | 18.8% | 18.8% | 18.9% | 867,494 | 16.0% | 15.9% | 16.1% | 753,435 | 22.1% | 22.0% | 22.2% |
| Ages <45 | 27,404 | 29.7% | 29.1% | 30.3% | 13,038 | 25.6% | 24.8% | 26.4% | 14,366 | 33.4% | 32.5% | 34.2% |
| Ages 45-54 | 135,493 | 22.5% | 22.2% | 22.7% | 70,255 | 18.2% | 17.9% | 18.5% | 65,238 | 27.1% | 26.8% | 27.5% |
| Ages 55-64 | 344,296 | 21.1% | 21.0% | 21.3% | 189,465 | 17.5% | 17.3% | 17.7% | 154,831 | 25.6% | 25.3% | 25.8% |
| Ages 65-74 | 538,384 | 20.0% | 19.8% | 20.1% | 293,626 | 17.0% | 16.9% | 17.2% | 244,758 | 23.5% | 23.3% | 23.7% |
| Ages 75+ | 584,480 | 14.8% | 14.7% | 14.9% | 305,307 | 12.8% | 12.7% | 13.0% | 279,173 | 16.9% | 16.7% | 17.1% |
| Ages <65 | 505,808 | 21.9% | 21.8% | 22.1% | 272,161 | 18.1% | 17.9% | 18.2% | 233,647 | 26.4% | 26.2% | 26.7% |
| Ages 65+ | 1,118,688 | 17.3% | 17.2% | 17.4% | 596,952 | 14.9% | 14.8% | 15.1% | 521,736 | 20.0% | 19.9% | 20.2% |

| Lung and Bronchus Cancer | | | | | | | | | | | | |
|--------------------------|-----------------|-------------------|---------|---------|--------------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | <u>Black</u> | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 200,110 | 16.2% | 16.0% | 16.4% | 114,380 | 13.9% | 13.7% | 14.2% | 85,730 | 19.3% | 18.9% | 19.6% |
| Ages <45 | 5,692 | 23.0% | 21.8% | 24.1% | 2,883 | 19.8% | 18.3% | 21.4% | 2,809 | 26.1% | 24.4% | 27.9% |
| Ages 45-54 | 29,623 | 18.1% | 17.6% | 18.6% | 16,685 | 14.7% | 14.1% | 15.3% | 12,938 | 22.5% | 21.7% | 23.3% |
| Ages 55-64 | 55,883 | 17.4% | 17.1% | 17.8% | 33,920 | 15.1% | 14.7% | 15.6% | 21,963 | 21.0% | 20.4% | 21.6% |
| Ages 65-74 | 61,155 | 16.3% | 16.0% | 16.7% | 35,643 | 13.9% | 13.5% | 14.4% | 25,512 | 19.7% | 19.1% | 20.3% |
| Ages 75+ | 48,678 | 12.4% | 12.0% | 12.9% | 25,719 | 10.9% | 10.3% | 11.4% | 22,959 | 14.2% | 13.5% | 14.8% |
| Ages <65 | 90,965 | 18.0% | 17.7% | 18.3% | 53,371 | 15.2% | 14.9% | 15.6% | 37,594 | 21.9% | 21.4% | 22.4% |
| Ages 65+ | 109,511 | 14.6% | 14.4% | 14.9% | 61,202 | 12.7% | 12.3% | 13.0% | 48,309 | 17.1% | 16.7% | 17.5% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 10. Five-Year Relative Survival*, Melanoma of the Skin, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Melanoma of the Skin | | | | | | | | | | | | |
|----------------------|-----------------|-------------------|---------|---------|-----------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Male and female | | | | All Races | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | Male | | | | N | Relative Survival | 95% LCI | 95% UCI |
| | | | | | N | Relative Survival | 95% LCI | 95% UCI | | | | |
| All Ages | 544,640 | 89.4% | 89.3% | 89.6% | 311,795 | 87.1% | 86.9% | 87.3% | 232,845 | 92.4% | 92.3% | 92.6% |
| Ages <45 | 98,738 | 93.9% | 93.7% | 94.1% | 38,963 | 90.5% | 90.2% | 90.8% | 59,775 | 96.1% | 95.9% | 96.3% |
| Ages 45-54 | 96,159 | 91.2% | 91.0% | 91.4% | 49,791 | 88.4% | 88.1% | 88.8% | 46,368 | 94.2% | 93.9% | 94.5% |
| Ages 55-64 | 114,662 | 89.6% | 89.3% | 89.8% | 70,657 | 87.8% | 87.5% | 88.2% | 44,005 | 92.4% | 92.0% | 92.7% |
| Ages 65-74 | 111,986 | 88.4% | 88.1% | 88.8% | 73,941 | 87.3% | 86.9% | 87.7% | 38,045 | 90.5% | 90.0% | 91.0% |
| Ages 75+ | 127,997 | 83.7% | 83.2% | 84.2% | 81,890 | 82.3% | 81.6% | 83.0% | 46,107 | 85.9% | 85.1% | 86.7% |
| Ages <65 | 307,998 | 91.6% | 91.4% | 91.7% | 158,498 | 88.8% | 88.6% | 89.0% | 149,500 | 94.5% | 94.4% | 94.7% |
| Ages 65+ | 238,157 | 86.1% | 85.8% | 86.4% | 154,429 | 84.9% | 84.5% | 85.3% | 83,728 | 88.1% | 87.6% | 88.6% |

| Melanoma of the Skin | | | | | | | | | | | | |
|----------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Male and female | | | | White | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | Male | | | | N | Relative Survival | 95% LCI | 95% UCI |
| | | | | | N | Relative Survival | 95% LCI | 95% UCI | | | | |
| All Ages | 517,765 | 89.1% | 88.9% | 89.2% | 298,329 | 86.7% | 86.5% | 86.9% | 219,436 | 92.2% | 92.0% | 92.4% |
| Ages <45 | 91,768 | 93.7% | 93.5% | 93.9% | 36,277 | 90.1% | 89.8% | 90.5% | 55,491 | 96.0% | 95.8% | 96.2% |
| Ages 45-54 | 90,601 | 90.9% | 90.6% | 91.1% | 47,125 | 88.0% | 87.6% | 88.4% | 43,476 | 94.0% | 93.7% | 94.3% |
| Ages 55-64 | 108,938 | 89.2% | 89.0% | 89.5% | 67,452 | 87.5% | 87.1% | 87.8% | 41,486 | 92.1% | 91.7% | 92.5% |
| Ages 65-74 | 107,475 | 88.1% | 87.8% | 88.4% | 71,257 | 87.0% | 86.5% | 87.4% | 36,218 | 90.3% | 89.8% | 90.8% |
| Ages 75+ | 123,818 | 83.2% | 82.7% | 83.7% | 79,619 | 81.8% | 81.1% | 82.5% | 44,199 | 85.5% | 84.7% | 86.3% |
| Ages <65 | 289,779 | 91.2% | 91.1% | 91.4% | 149,961 | 88.4% | 88.1% | 88.6% | 139,818 | 94.3% | 94.2% | 94.5% |
| Ages 65+ | 229,487 | 85.7% | 85.4% | 86.0% | 149,492 | 84.5% | 84.1% | 84.9% | 79,995 | 87.8% | 87.3% | 88.3% |

| Melanoma of the Skin | | | | | | | | | | | | |
|----------------------|-----------------|-------------------|---------|---------|-------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | Black | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | Male | | | | N | Relative Survival | 95% LCI | 95% UCI |
| | | | | | N | Relative Survival | 95% LCI | 95% UCI | | | | |
| All Ages | 3,048 | 66.1% | 63.7% | 68.3% | 1,321 | 59.5% | 55.8% | 63.1% | 1,727 | 70.9% | 67.9% | 73.7% |
| Ages <45 | 532 | 75.8% | 71.5% | 79.6% | 212 | 64.1% | 56.3% | 70.8% | 320 | 83.5% | 78.4% | 87.4% |
| Ages 45-54 | 465 | 68.9% | 63.7% | 73.6% | 210 | 62.4% | 54.1% | 69.6% | 255 | 74.1% | 67.2% | 79.8% |
| Ages 55-64 | 629 | 65.3% | 60.4% | 69.7% | 301 | 54.2% | 46.9% | 60.9% | 328 | 75.5% | 69.0% | 80.8% |
| Ages 65-74 | 639 | 63.5% | 58.1% | 68.4% | 289 | 61.9% | 53.3% | 69.3% | 350 | 64.8% | 57.7% | 71.1% |
| Ages 75+ | 802 | 58.6% | 52.3% | 64.3% | 319 | 55.7% | 45.1% | 65.1% | 483 | 60.2% | 52.4% | 67.2% |
| Ages <65 | 1,616 | 70.0% | 67.3% | 72.6% | 719 | 59.5% | 55.1% | 63.7% | 897 | 78.4% | 75.0% | 81.3% |
| Ages 65+ | 1,435 | 60.9% | 56.8% | 64.8% | 603 | 59.2% | 52.5% | 65.3% | 832 | 62.1% | 56.8% | 66.9% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 11. Five-Year Relative Survival*, Female Breast Cancer, by Race, and Age Group — National Program of Cancer Registries[¶], 2001-2013.

| Age group | Female Breast Cancer | | | | | | | | | | | |
|------------|----------------------|-------------------|---------|---------|-----------|-------------------|---------|---------|---------|-------------------|---------|---------|
| | All races | | | | White | | | | Black | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 1,896,726 | 88.8% | 88.7% | 88.9% | 1,599,804 | 89.9% | 89.8% | 90.0% | 213,859 | 79.4% | 79.2% | 79.6% |
| Ages <45 | 213,712 | 87.5% | 87.4% | 87.7% | 163,289 | 89.2% | 89.0% | 89.3% | 34,813 | 78.1% | 77.6% | 78.6% |
| Ages 45-54 | 406,121 | 89.5% | 89.4% | 89.7% | 328,326 | 90.9% | 90.8% | 91.0% | 54,492 | 80.0% | 79.6% | 80.4% |
| Ages 55-64 | 469,266 | 89.4% | 89.3% | 89.5% | 393,814 | 90.4% | 90.3% | 90.6% | 54,349 | 80.4% | 79.9% | 80.8% |
| Ages 65-74 | 417,094 | 89.7% | 89.5% | 89.8% | 362,170 | 90.5% | 90.4% | 90.7% | 40,467 | 81.2% | 80.6% | 81.8% |
| Ages 75+ | 406,386 | 87.1% | 86.9% | 87.4% | 365,243 | 88.1% | 87.8% | 88.3% | 32,009 | 75.5% | 74.5% | 76.4% |
| Ages <65 | 1,082,030 | 89.1% | 89.0% | 89.2% | 880,008 | 90.4% | 90.3% | 90.5% | 142,339 | 79.7% | 79.5% | 80.0% |
| Ages 65+ | 819,599 | 88.4% | 88.3% | 88.6% | 723,960 | 89.3% | 89.1% | 89.4% | 72,114 | 78.8% | 78.2% | 79.3% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[¶]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 12. Five-Year Relative Survival*, Cervical Cancer (Cervix Uteri), by Race, and Age Group — National Program of Cancer Registries[¶], 2001-2013.

| Cervical Cancer (Cervix Uteri) | | | | | | | | | | | | |
|--------------------------------|-----------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | All races | | | | White | | | | Black | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 117,086 | 67.7% | 67.4% | 68.0% | 88,890 | 69.0% | 68.7% | 69.4% | 20,307 | 58.3% | 57.5% | 59.1% |
| Ages <45 | 45,419 | 80.1% | 79.7% | 80.5% | 35,639 | 81.9% | 81.4% | 82.3% | 6,772 | 68.6% | 67.3% | 69.8% |
| Ages 45-54 | 27,565 | 68.1% | 67.5% | 68.7% | 20,708 | 69.5% | 68.7% | 70.2% | 4,923 | 58.8% | 57.3% | 60.4% |
| Ages 55-64 | 20,362 | 60.5% | 59.7% | 61.3% | 15,120 | 60.7% | 59.8% | 61.6% | 3,748 | 54.7% | 52.8% | 56.5% |
| Ages 65-74 | 12,999 | 54.9% | 53.9% | 55.9% | 9,548 | 55.0% | 53.8% | 56.2% | 2,604 | 49.9% | 47.5% | 52.3% |
| Ages 75+ | 10,809 | 39.2% | 37.8% | 40.5% | 7,916 | 38.3% | 36.7% | 39.8% | 2,282 | 39.4% | 36.4% | 42.3% |
| Ages <65 | 93,300 | 72.4% | 72.1% | 72.7% | 71,438 | 73.9% | 73.6% | 74.3% | 15,429 | 62.2% | 61.3% | 63.0% |
| Ages 65+ | 23,799 | 48.0% | 47.2% | 48.8% | 17,459 | 47.7% | 46.7% | 48.6% | 4,883 | 45.1% | 43.2% | 46.9% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

¶Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 13. Five-Year Relative Survival*, Uterine Cancer (Corpus and Uterus, NOS,) by Race, and Age Group — National Program of Cancer Registries[¶], 2001-2013.

| Age group | Uterine Cancer (Corpus and Uterus, NOS) | | | | | | | | | | | |
|------------|---|-------------------|---------|---------|---------|-------------------|---------|---------|--------|-------------------|---------|---------|
| | All races | | | | White | | | | Black | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 406,365 | 80.5% | 80.3% | 80.6% | 345,807 | 82.6% | 82.4% | 82.8% | 42,624 | 60.7% | 60.1% | 61.3% |
| Ages <45 | 28,059 | 89.8% | 89.4% | 90.2% | 22,299 | 90.6% | 90.2% | 91.1% | 3,279 | 82.2% | 80.7% | 83.7% |
| Ages 45-54 | 70,879 | 88.1% | 87.8% | 88.4% | 60,298 | 89.4% | 89.1% | 89.7% | 5,794 | 72.0% | 70.7% | 73.4% |
| Ages 55-64 | 130,323 | 84.2% | 83.9% | 84.4% | 110,655 | 86.5% | 86.3% | 86.8% | 13,870 | 63.7% | 62.7% | 64.7% |
| Ages 65-74 | 100,102 | 77.2% | 76.8% | 77.5% | 84,628 | 80.2% | 79.8% | 80.5% | 12,345 | 55.8% | 54.7% | 57.0% |
| Ages 75+ | 77,132 | 66.7% | 66.1% | 67.2% | 68,026 | 69.2% | 68.6% | 69.8% | 7,363 | 42.5% | 40.8% | 44.2% |
| Ages <65 | 229,218 | 86.2% | 86.0% | 86.3% | 193,220 | 88.0% | 87.8% | 88.2% | 22,934 | 68.7% | 68.0% | 69.4% |
| Ages 65+ | 177,195 | 72.7% | 72.3% | 73.0% | 152,626 | 75.3% | 75.0% | 75.7% | 19,698 | 51.0% | 50.0% | 52.0% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[¶]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 14. Five-Year Relative Survival*, Ovarian Cancer, by Race, and Age Group — National Program of Cancer Registries[¶], 2001-2013.

| Age group | Ovarian Cancer | | | | | | | | | | | |
|-----------------|----------------|-------------------|--------------|--------------|----------------|-------------------|--------------|--------------|---------------|-------------------|--------------|--------------|
| | All races | | | | White | | | | Black | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 198,866 | 45.8% | 45.6% | 46.1% | 172,353 | 45.9% | 45.6% | 46.2% | 17,575 | 38.6% | 37.8% | 39.5% |
| Ages <45 | 22,869 | 75.4% | 74.8% | 76.0% | 18,176 | 75.5% | 74.8% | 76.2% | 2,755 | 72.5% | 70.6% | 74.3% |
| Ages 45-54 | 36,386 | 60.0% | 59.4% | 60.6% | 30,676 | 61.1% | 60.5% | 61.7% | 3,360 | 45.8% | 43.8% | 47.8% |
| Ages 55-64 | 46,325 | 49.4% | 48.8% | 49.9% | 40,107 | 50.2% | 49.6% | 50.8% | 4,107 | 36.0% | 34.2% | 37.8% |
| Ages 65-74 | 42,963 | 38.2% | 37.6% | 38.7% | 37,809 | 39.2% | 38.6% | 39.8% | 3,759 | 26.1% | 24.4% | 27.9% |
| Ages 75+ | 50,377 | 22.8% | 22.3% | 23.3% | 45,635 | 23.0% | 22.5% | 23.5% | 3,596 | 18.4% | 16.6% | 20.2% |
| Ages <65 | 105,552 | 58.8% | 58.5% | 59.2% | 88,934 | 59.3% | 58.9% | 59.7% | 10,221 | 49.6% | 48.4% | 50.7% |
| Ages 65+ | 93,329 | 30.0% | 29.7% | 30.4% | 83,433 | 30.5% | 30.1% | 30.9% | 7,355 | 22.4% | 21.1% | 23.6% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[¶]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 15. Five-Year Relative Survival*, Prostate Cancer, by Race, and Age Group — National Program of Cancer Registries[¶], 2001-2013.

| Age group | Prostate Cancer | | | | | | | | | | | |
|-----------------|------------------|-------------------|--------------|--------------|------------------|-------------------|--------------|--------------|----------------|-------------------|--------------|--------------|
| | All races | | | | White | | | | Black | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 1,988,265 | 97.8% | 97.8% | 97.9% | 1,595,712 | 97.9% | 97.9% | 98.0% | 297,202 | 95.7% | 95.5% | 95.9% |
| Ages <45 | 11,729 | 95.6% | 95.1% | 96.0% | 7,720 | 95.2% | 94.5% | 95.7% | 3,440 | 96.3% | 95.2% | 97.1% |
| Ages 45-54 | 183,420 | 97.8% | 97.6% | 97.9% | 134,380 | 97.9% | 97.7% | 98.0% | 41,117 | 97.0% | 96.7% | 97.3% |
| Ages 55-64 | 611,723 | 98.9% | 98.8% | 99.0% | 477,163 | 99.0% | 99.0% | 99.1% | 107,033 | 97.6% | 97.3% | 97.8% |
| Ages 65-74 | 742,091 | 99.5% | 99.3% | 99.6% | 604,637 | 99.6% | 99.5% | 99.7% | 100,855 | 97.0% | 96.7% | 97.4% |
| Ages 75+ | 439,337 | 93.7% | 93.5% | 94.0% | 371,844 | 93.8% | 93.5% | 94.1% | 44,760 | 86.6% | 85.7% | 87.4% |
| Ages <65 | 806,868 | 98.6% | 98.5% | 98.6% | 619,260 | 98.7% | 98.7% | 98.8% | 151,589 | 97.4% | 97.2% | 97.6% |
| Ages 65+ | 1,181,408 | 97.4% | 97.2% | 97.5% | 976,461 | 97.5% | 97.3% | 97.6% | 145,615 | 93.9% | 93.6% | 94.3% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[¶]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 16. Five-Year Relative Survival*, Testicular Cancer, by Race, and Age Group — National Program of Cancer Registries[¶], 2001-2013.

| Testicular Cancer | | | | | | | | | | | | |
|-------------------|---------------|-------------------|--------------|--------------|---------------|-------------------|--------------|--------------|--------------|-------------------|--------------|--------------|
| Age group | All races | | | | White | | | | Black | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 73,413 | 95.3% | 95.1% | 95.5% | 67,659 | 95.5% | 95.3% | 95.7% | 2,519 | 89.9% | 88.3% | 91.2% |
| Ages <45 | 58,034 | 96.0% | 95.8% | 96.1% | 53,283 | 96.1% | 95.9% | 96.3% | 1,974 | 91.4% | 89.8% | 92.7% |
| Ages 45-54 | 10,433 | 95.1% | 94.6% | 95.6% | 9,753 | 95.3% | 94.7% | 95.8% | 365 | 88.0% | 83.2% | 91.4% |
| Ages 55-64 | 3,294 | 91.4% | 89.9% | 92.7% | 3,075 | 91.5% | 89.9% | 92.8% | 122 | 84.2% | 71.6% | 91.5% |
| Ages 65-74 | 1,026 | 84.5% | 80.7% | 87.7% | 969 | 85.0% | 81.0% | 88.2% | 33 | 74.6% | 50.4% | 88.2% |
| Ages 75+ | 659 | 72.7% | 65.2% | 78.9% | 612 | 74.5% | 66.6% | 80.9% | 25 | 29.0% | 7.7% | 54.9% |
| Ages <65 | 71,729 | 95.6% | 95.5% | 95.8% | 66,079 | 95.8% | 95.6% | 96.0% | 2,461 | 90.6% | 89.1% | 91.9% |
| Ages 65+ | 1,685 | 80.2% | 76.6% | 83.3% | 1,581 | 81.2% | 77.5% | 84.4% | 58 | 58.3% | 37.9% | 74.1% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[¶]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 17. Five-Year Relative Survival*, Urinary Bladder Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Urinary Bladder Cancer | | | | | | | | | | | | |
|------------------------|-----------------|-------------------|---------|---------|-----------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Male and female | | | | All Races | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | Male | | | | N | Relative Survival | 95% LCI | 95% UCI |
| | | | | | N | Relative Survival | 95% LCI | 95% UCI | | | | |
| All Ages | 625,425 | 75.6% | 75.4% | 75.7% | 469,225 | 76.8% | 76.6% | 77.0% | 156,200 | 72.0% | 71.6% | 72.3% |
| Ages <45 | 13,830 | 88.0% | 87.4% | 88.6% | 9,769 | 89.2% | 88.5% | 89.9% | 4,061 | 85.2% | 84.0% | 86.3% |
| Ages 45-54 | 45,193 | 83.8% | 83.4% | 84.2% | 33,570 | 84.5% | 84.1% | 85.0% | 11,623 | 81.7% | 80.9% | 82.5% |
| Ages 55-64 | 114,316 | 81.6% | 81.4% | 81.9% | 87,476 | 82.0% | 81.6% | 82.3% | 26,840 | 80.6% | 80.0% | 81.1% |
| Ages 65-74 | 182,598 | 77.4% | 77.1% | 77.7% | 141,078 | 78.1% | 77.7% | 78.4% | 41,520 | 75.1% | 74.6% | 75.7% |
| Ages 75+ | 272,127 | 68.7% | 68.4% | 69.0% | 199,476 | 70.5% | 70.1% | 70.9% | 72,651 | 63.8% | 63.2% | 64.4% |
| Ages <65 | 172,974 | 82.8% | 82.5% | 83.0% | 130,514 | 83.2% | 83.0% | 83.5% | 42,460 | 81.3% | 80.9% | 81.8% |
| Ages 65+ | 453,313 | 72.4% | 72.2% | 72.6% | 339,411 | 73.9% | 73.6% | 74.1% | 113,902 | 68.1% | 67.7% | 68.5% |

| Urinary Bladder Cancer | | | | | | | | | | | | |
|------------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Male and female | | | | White | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | Male | | | | N | Relative Survival | 95% LCI | 95% UCI |
| | | | | | N | Relative Survival | 95% LCI | 95% UCI | | | | |
| All Ages | 575,222 | 76.0% | 75.8% | 76.1% | 434,566 | 76.9% | 76.7% | 77.1% | 140,656 | 73.0% | 72.7% | 73.4% |
| Ages <45 | 11,997 | 89.1% | 88.4% | 89.7% | 8,458 | 89.9% | 89.2% | 90.6% | 3,539 | 87.0% | 85.8% | 88.2% |
| Ages 45-54 | 39,981 | 84.7% | 84.3% | 85.1% | 29,797 | 85.0% | 84.5% | 85.5% | 10,184 | 83.6% | 82.8% | 84.4% |
| Ages 55-64 | 103,570 | 82.2% | 81.9% | 82.5% | 79,562 | 82.2% | 81.9% | 82.6% | 24,008 | 81.9% | 81.3% | 82.5% |
| Ages 65-74 | 167,992 | 77.8% | 77.5% | 78.1% | 130,716 | 78.2% | 77.9% | 78.6% | 37,276 | 76.1% | 75.6% | 76.7% |
| Ages 75+ | 254,143 | 69.1% | 68.8% | 69.5% | 188,057 | 70.7% | 70.2% | 71.1% | 66,086 | 64.7% | 64.1% | 65.3% |
| Ages <65 | 155,210 | 83.4% | 83.2% | 83.6% | 117,539 | 83.6% | 83.3% | 83.8% | 37,671 | 82.9% | 82.4% | 83.3% |
| Ages 65+ | 420,821 | 72.8% | 72.6% | 73.0% | 317,692 | 74.0% | 73.7% | 74.3% | 103,129 | 69.0% | 68.6% | 69.5% |

| Urinary Bladder Cancer | | | | | | | | | | | | |
|------------------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | Black | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | Male | | | | N | Relative Survival | 95% LCI | 95% UCI |
| | | | | | N | Relative Survival | 95% LCI | 95% UCI | | | | |
| All Ages | 32,809 | 63.2% | 62.4% | 63.9% | 21,587 | 67.9% | 66.9% | 68.8% | 11,222 | 54.3% | 53.0% | 55.5% |
| Ages <45 | 1,024 | 71.8% | 68.6% | 74.7% | 736 | 76.5% | 72.9% | 79.8% | 288 | 59.6% | 53.2% | 65.4% |
| Ages 45-54 | 3,401 | 69.4% | 67.5% | 71.1% | 2,407 | 73.8% | 71.6% | 75.8% | 994 | 58.8% | 55.2% | 62.1% |
| Ages 55-64 | 7,078 | 68.6% | 67.2% | 70.0% | 5,086 | 72.1% | 70.4% | 73.7% | 1,992 | 60.1% | 57.5% | 62.6% |
| Ages 65-74 | 9,582 | 65.1% | 63.7% | 66.4% | 6,509 | 68.7% | 67.0% | 70.4% | 3,073 | 57.6% | 55.3% | 59.9% |
| Ages 75+ | 11,853 | 54.8% | 53.2% | 56.4% | 6,934 | 59.6% | 57.4% | 61.8% | 4,919 | 48.3% | 46.0% | 50.5% |
| Ages <65 | 11,478 | 69.2% | 68.1% | 70.2% | 8,208 | 73.0% | 71.8% | 74.2% | 3,270 | 59.6% | 57.6% | 61.6% |
| Ages 65+ | 21,366 | 59.6% | 58.6% | 60.7% | 13,401 | 64.3% | 62.9% | 65.7% | 7,965 | 52.0% | 50.4% | 53.6% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 18. Five-Year Relative Survival*, Kidney and Renal Pelvis Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Kidney and Renal Pelvis Cancer | | | | | | | | | | | | |
|--------------------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | All Races | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 439,827 | 71.2% | 71.0% | 71.3% | 271,959 | 70.7% | 70.5% | 71.0% | 167,868 | 71.8% | 71.5% | 72.1% |
| Ages <45 | 38,791 | 86.2% | 85.8% | 86.6% | 22,767 | 84.6% | 84.1% | 85.2% | 16,024 | 88.5% | 87.9% | 89.0% |
| Ages 45-54 | 70,314 | 78.6% | 78.3% | 79.0% | 45,772 | 76.8% | 76.4% | 77.3% | 24,542 | 82.0% | 81.5% | 82.6% |
| Ages 55-64 | 110,878 | 73.8% | 73.5% | 74.1% | 72,556 | 72.4% | 72.0% | 72.8% | 38,322 | 76.4% | 75.8% | 76.9% |
| Ages 65-74 | 115,783 | 69.7% | 69.3% | 70.0% | 73,100 | 69.2% | 68.7% | 69.7% | 42,683 | 70.4% | 69.8% | 70.9% |
| Ages 75+ | 105,494 | 58.5% | 58.0% | 58.9% | 58,766 | 59.4% | 58.7% | 60.0% | 46,728 | 57.3% | 56.6% | 58.0% |
| Ages <65 | 219,405 | 77.6% | 77.4% | 77.8% | 140,700 | 75.9% | 75.6% | 76.1% | 78,705 | 80.6% | 80.3% | 81.0% |
| Ages 65+ | 220,938 | 64.4% | 64.1% | 64.7% | 131,627 | 64.9% | 64.5% | 65.3% | 89,311 | 63.7% | 63.2% | 64.1% |

| Kidney and Renal Pelvis Cancer | | | | | | | | | | | | |
|--------------------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | White | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 375,527 | 71.1% | 70.9% | 71.3% | 233,347 | 70.7% | 70.5% | 71.0% | 142,180 | 71.7% | 71.4% | 72.0% |
| Ages <45 | 30,860 | 87.5% | 87.1% | 87.9% | 18,129 | 86.0% | 85.5% | 86.6% | 12,731 | 89.7% | 89.0% | 90.2% |
| Ages 45-54 | 57,665 | 78.9% | 78.5% | 79.3% | 37,598 | 76.9% | 76.4% | 77.4% | 20,067 | 82.5% | 81.9% | 83.1% |
| Ages 55-64 | 92,965 | 73.9% | 73.6% | 74.3% | 61,166 | 72.5% | 72.1% | 73.0% | 31,799 | 76.6% | 76.0% | 77.1% |
| Ages 65-74 | 100,238 | 69.7% | 69.3% | 70.0% | 63,813 | 69.2% | 68.7% | 69.7% | 36,425 | 70.4% | 69.8% | 71.0% |
| Ages 75+ | 94,930 | 58.7% | 58.2% | 59.2% | 53,427 | 59.7% | 59.0% | 60.4% | 41,503 | 57.4% | 56.7% | 58.2% |
| Ages <65 | 181,056 | 77.9% | 77.6% | 78.1% | 116,610 | 76.1% | 75.8% | 76.4% | 64,446 | 81.0% | 80.7% | 81.4% |
| Ages 65+ | 194,885 | 64.4% | 64.1% | 64.7% | 117,034 | 65.0% | 64.6% | 65.4% | 77,851 | 63.6% | 63.1% | 64.1% |

| Kidney and Renal Pelvis Cancer | | | | | | | | | | | | |
|--------------------------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Black | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 49,910 | 70.5% | 69.9% | 71.0% | 29,573 | 69.8% | 69.1% | 70.5% | 20,337 | 71.5% | 70.7% | 72.3% |
| Ages <45 | 5,893 | 78.7% | 77.5% | 79.9% | 3,419 | 76.0% | 74.3% | 77.6% | 2,474 | 82.5% | 80.7% | 84.1% |
| Ages 45-54 | 9,866 | 76.0% | 75.0% | 77.0% | 6,326 | 74.6% | 73.3% | 75.9% | 3,540 | 78.5% | 76.8% | 80.1% |
| Ages 55-64 | 14,160 | 72.2% | 71.2% | 73.1% | 8,921 | 70.6% | 69.3% | 71.8% | 5,239 | 74.8% | 73.3% | 76.3% |
| Ages 65-74 | 12,240 | 69.0% | 67.8% | 70.1% | 7,203 | 68.4% | 66.8% | 70.0% | 5,037 | 69.8% | 68.0% | 71.5% |
| Ages 75+ | 8,023 | 55.5% | 53.6% | 57.3% | 3,902 | 55.8% | 53.0% | 58.5% | 4,121 | 55.1% | 52.7% | 57.5% |
| Ages <65 | 29,788 | 74.8% | 74.1% | 75.4% | 18,563 | 72.9% | 72.1% | 73.7% | 11,225 | 77.8% | 76.8% | 78.7% |
| Ages 65+ | 20,212 | 63.8% | 62.7% | 64.8% | 11,074 | 64.1% | 62.7% | 65.5% | 9,138 | 63.3% | 61.8% | 64.7% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 19. Five-Year Relative Survival*, Brain and Other Nervous System Tumors, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Brain and Other Nervous System Tumors | | | | | | | | | | | | |
|---------------------------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | All Races | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 189,454 | 32.3% | 32.0% | 32.5% | 104,632 | 30.9% | 30.6% | 31.3% | 84,822 | 33.9% | 33.5% | 34.2% |
| Ages <45 | 56,946 | 68.2% | 67.7% | 68.6% | 31,695 | 65.9% | 65.4% | 66.5% | 25,251 | 70.9% | 70.3% | 71.6% |
| Ages 45-54 | 27,407 | 32.4% | 31.8% | 33.0% | 16,016 | 29.2% | 28.4% | 30.0% | 11,391 | 36.9% | 35.9% | 37.9% |
| Ages 55-64 | 36,333 | 17.5% | 17.1% | 18.0% | 20,944 | 15.6% | 15.0% | 16.2% | 15,389 | 20.2% | 19.4% | 20.9% |
| Ages 65-74 | 34,384 | 10.1% | 9.7% | 10.5% | 19,204 | 9.0% | 8.5% | 9.5% | 15,180 | 11.5% | 10.9% | 12.1% |
| Ages 75+ | 34,492 | 6.3% | 6.0% | 6.7% | 16,830 | 5.7% | 5.2% | 6.2% | 17,662 | 6.9% | 6.4% | 7.4% |
| Ages <65 | 120,596 | 45.2% | 44.9% | 45.5% | 68,610 | 42.4% | 42.0% | 42.8% | 51,986 | 48.8% | 48.3% | 49.3% |
| Ages 65+ | 68,870 | 8.2% | 8.0% | 8.5% | 36,030 | 7.5% | 7.1% | 7.8% | 32,840 | 9.0% | 8.6% | 9.4% |

| Brain and Other Nervous System Tumors | | | | | | | | | | | | |
|---------------------------------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | White | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 167,951 | 31.0% | 30.7% | 31.2% | 93,171 | 29.9% | 29.5% | 30.2% | 74,780 | 32.4% | 32.0% | 32.8% |
| Ages <45 | 47,435 | 68.7% | 68.2% | 69.1% | 26,608 | 66.5% | 65.8% | 67.1% | 20,827 | 71.5% | 70.8% | 72.1% |
| Ages 45-54 | 24,192 | 31.8% | 31.2% | 32.5% | 14,207 | 28.6% | 27.8% | 29.5% | 9,985 | 36.3% | 35.3% | 37.4% |
| Ages 55-64 | 32,841 | 16.9% | 16.5% | 17.4% | 19,019 | 15.1% | 14.5% | 15.8% | 13,822 | 19.4% | 18.6% | 20.1% |
| Ages 65-74 | 31,486 | 9.7% | 9.3% | 10.1% | 17,655 | 8.7% | 8.2% | 9.2% | 13,831 | 10.8% | 10.2% | 11.5% |
| Ages 75+ | 32,092 | 5.9% | 5.5% | 6.3% | 15,735 | 5.4% | 4.9% | 5.9% | 16,357 | 6.3% | 5.9% | 6.9% |
| Ages <65 | 104,388 | 44.3% | 44.0% | 44.6% | 59,791 | 41.6% | 41.2% | 42.1% | 44,597 | 47.8% | 47.3% | 48.3% |
| Ages 65+ | 63,572 | 7.8% | 7.5% | 8.0% | 33,386 | 7.1% | 6.8% | 7.5% | 30,186 | 8.4% | 8.0% | 8.8% |

| Brain and Other Nervous System Tumors | | | | | | | | | | | | |
|---------------------------------------|-----------------|-------------------|---------|---------|-------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Black | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 14,178 | 38.9% | 37.9% | 39.8% | 7,402 | 36.2% | 35.0% | 37.5% | 6,776 | 41.7% | 40.4% | 43.0% |
| Ages <45 | 6,008 | 63.2% | 61.8% | 64.5% | 3,147 | 60.5% | 58.5% | 62.3% | 2,861 | 66.2% | 64.2% | 68.0% |
| Ages 45-54 | 2,203 | 32.5% | 30.3% | 34.7% | 1,211 | 28.2% | 25.3% | 31.1% | 992 | 37.6% | 34.2% | 41.0% |
| Ages 55-64 | 2,393 | 20.4% | 18.5% | 22.3% | 1,323 | 17.3% | 14.9% | 19.9% | 1,070 | 24.1% | 21.2% | 27.1% |
| Ages 65-74 | 1,968 | 12.4% | 10.6% | 14.3% | 1,024 | 9.3% | 7.2% | 11.8% | 944 | 15.6% | 12.9% | 18.5% |
| Ages 75+ | 1,617 | 10.8% | 8.8% | 13.2% | 701 | 8.3% | 5.5% | 11.7% | 916 | 12.7% | 9.8% | 15.9% |
| Ages <65 | 10,595 | 47.5% | 46.4% | 48.5% | 5,679 | 43.9% | 42.5% | 45.4% | 4,916 | 51.5% | 50.0% | 53.0% |
| Ages 65+ | 3,585 | 11.6% | 10.2% | 13.0% | 1,725 | 8.8% | 7.1% | 10.7% | 1,860 | 14.1% | 12.1% | 16.2% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 20. Five-Year Relative Survival*, Thyroid Cancer, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Thyroid Cancer | | | | | | | | | | | | |
|----------------|-----------------|-------------------|---------|---------|-----------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Male and female | | | | All Races | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 333,730 | 96.8% | 96.7% | 96.9% | 80,648 | 93.4% | 93.1% | 93.7% | 253,082 | 97.8% | 97.7% | 97.9% |
| Ages <45 | 123,438 | 99.4% | 99.3% | 99.5% | 22,253 | 98.4% | 98.1% | 98.6% | 101,185 | 99.6% | 99.6% | 99.7% |
| Ages 45-54 | 78,998 | 98.3% | 98.1% | 98.4% | 17,988 | 95.6% | 95.1% | 96.0% | 61,010 | 99.0% | 98.9% | 99.2% |
| Ages 55-64 | 63,955 | 96.2% | 96.0% | 96.5% | 18,580 | 93.0% | 92.4% | 93.6% | 45,375 | 97.6% | 97.3% | 97.8% |
| Ages 65-74 | 42,454 | 93.1% | 92.7% | 93.6% | 13,798 | 89.5% | 88.6% | 90.4% | 28,656 | 94.8% | 94.3% | 95.3% |
| Ages 75+ | 25,081 | 85.4% | 84.5% | 86.2% | 8,090 | 81.1% | 79.1% | 82.9% | 16,991 | 86.7% | 85.8% | 87.5% |
| Ages <65 | 266,280 | 98.3% | 98.3% | 98.4% | 58,794 | 95.9% | 95.6% | 96.1% | 207,486 | 99.0% | 99.0% | 99.1% |
| Ages 65+ | 67,505 | 90.3% | 89.9% | 90.8% | 21,874 | 86.5% | 85.5% | 87.3% | 45,631 | 92.1% | 91.6% | 92.7% |

| Thyroid Cancer | | | | | | | | | | | | |
|----------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Male and female | | | | White | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 283,521 | 96.9% | 96.7% | 97.0% | 71,027 | 93.5% | 93.1% | 93.8% | 212,494 | 98.0% | 97.9% | 98.1% |
| Ages <45 | 103,323 | 99.5% | 99.4% | 99.5% | 19,012 | 98.5% | 98.2% | 98.7% | 84,311 | 99.7% | 99.6% | 99.7% |
| Ages 45-54 | 66,920 | 98.3% | 98.1% | 98.5% | 15,847 | 95.6% | 95.0% | 96.0% | 51,073 | 99.1% | 99.0% | 99.3% |
| Ages 55-64 | 54,429 | 96.4% | 96.1% | 96.6% | 16,466 | 93.0% | 92.4% | 93.6% | 37,963 | 97.8% | 97.5% | 98.1% |
| Ages 65-74 | 36,655 | 93.4% | 92.8% | 93.8% | 12,347 | 89.7% | 88.7% | 90.6% | 24,308 | 95.2% | 94.6% | 95.7% |
| Ages 75+ | 22,367 | 86.2% | 85.3% | 87.0% | 7,409 | 81.7% | 79.6% | 83.6% | 14,958 | 87.5% | 86.7% | 88.2% |
| Ages <65 | 224,571 | 98.4% | 98.3% | 98.5% | 51,300 | 95.9% | 95.6% | 96.1% | 173,271 | 99.1% | 99.0% | 99.2% |
| Ages 65+ | 58,993 | 90.7% | 90.2% | 91.2% | 19,743 | 86.7% | 85.8% | 87.7% | 39,250 | 92.6% | 92.1% | 93.1% |

| Thyroid Cancer | | | | | | | | | | | | |
|----------------|-----------------|-------------------|---------|---------|-------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | Black | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 26,022 | 95.4% | 94.9% | 95.8% | 4,666 | 91.2% | 89.7% | 92.4% | 21,356 | 96.3% | 95.8% | 96.7% |
| Ages <45 | 9,092 | 98.9% | 98.5% | 99.2% | 1,285 | 96.5% | 94.8% | 97.7% | 7,807 | 99.3% | 98.9% | 99.5% |
| Ages 45-54 | 6,424 | 97.2% | 96.4% | 97.8% | 1,064 | 93.4% | 91.0% | 95.2% | 5,360 | 97.9% | 97.1% | 98.5% |
| Ages 55-64 | 5,564 | 94.8% | 93.6% | 95.7% | 1,138 | 91.0% | 87.7% | 93.5% | 4,426 | 95.8% | 94.6% | 96.7% |
| Ages 65-74 | 3,376 | 90.5% | 88.5% | 92.2% | 810 | 86.4% | 81.9% | 89.8% | 2,566 | 91.5% | 89.2% | 93.4% |
| Ages 75+ | 1,579 | 78.0% | 73.6% | 81.8% | 370 | 71.8% | 62.8% | 79.0% | 1,209 | 79.9% | 74.9% | 84.0% |
| Ages <65 | 21,073 | 97.3% | 97.0% | 97.7% | 3,487 | 93.9% | 92.6% | 95.1% | 17,586 | 98.0% | 97.6% | 98.4% |
| Ages 65+ | 4,955 | 86.6% | 84.6% | 88.3% | 1,180 | 81.9% | 77.8% | 85.3% | 3,775 | 87.8% | 85.7% | 89.7% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 21. Five-Year Relative Survival*, Hodgkin Lymphoma, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Hodgkin Lymphoma | | | | | | | | | | | | |
|------------------|-----------------|-------------------|---------|---------|-----------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | All Races | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 79,056 | 83.3% | 83.0% | 83.6% | 43,287 | 81.9% | 81.5% | 82.4% | 35,769 | 84.9% | 84.5% | 85.4% |
| Ages <45 | 46,719 | 93.1% | 92.8% | 93.3% | 24,800 | 91.8% | 91.4% | 92.2% | 21,919 | 94.5% | 94.2% | 94.9% |
| Ages 45-54 | 9,984 | 85.1% | 84.2% | 85.9% | 6,244 | 83.1% | 82.0% | 84.2% | 3,740 | 88.3% | 87.0% | 89.5% |
| Ages 55-64 | 8,225 | 74.7% | 73.6% | 75.9% | 4,899 | 73.0% | 71.4% | 74.5% | 3,326 | 77.3% | 75.5% | 78.9% |
| Ages 65-74 | 7,068 | 61.1% | 59.7% | 62.6% | 3,963 | 58.9% | 56.8% | 60.8% | 3,105 | 64.0% | 61.9% | 66.1% |
| Ages 75+ | 7,069 | 42.9% | 41.2% | 44.6% | 3,383 | 41.1% | 38.5% | 43.6% | 3,686 | 44.5% | 42.1% | 46.8% |
| Ages <65 | 64,921 | 89.6% | 89.3% | 89.9% | 35,941 | 87.8% | 87.4% | 88.2% | 28,980 | 91.8% | 91.4% | 92.2% |
| Ages 65+ | 14,136 | 52.3% | 51.1% | 53.4% | 7,346 | 51.0% | 49.4% | 52.5% | 6,790 | 53.6% | 52.0% | 55.2% |

| Hodgkin Lymphoma | | | | | | | | | | | | |
|------------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | White | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 65,958 | 83.3% | 83.0% | 83.7% | 36,127 | 82.3% | 81.8% | 82.8% | 29,831 | 84.5% | 84.0% | 85.0% |
| Ages <45 | 37,986 | 93.9% | 93.7% | 94.2% | 20,154 | 93.0% | 92.6% | 93.4% | 17,832 | 95.0% | 94.6% | 95.4% |
| Ages 45-54 | 8,064 | 86.3% | 85.4% | 87.1% | 5,059 | 84.7% | 83.5% | 85.8% | 3,005 | 88.9% | 87.5% | 90.2% |
| Ages 55-64 | 6,961 | 75.8% | 74.5% | 77.0% | 4,170 | 74.8% | 73.1% | 76.4% | 2,791 | 77.3% | 75.4% | 79.1% |
| Ages 65-74 | 6,366 | 61.0% | 59.4% | 62.5% | 3,583 | 58.7% | 56.6% | 60.8% | 2,783 | 63.7% | 61.5% | 65.9% |
| Ages 75+ | 6,589 | 42.8% | 41.0% | 44.6% | 3,163 | 40.5% | 37.8% | 43.1% | 3,426 | 44.9% | 42.4% | 47.2% |
| Ages <65 | 53,005 | 90.5% | 90.2% | 90.8% | 29,381 | 89.1% | 88.7% | 89.5% | 23,624 | 92.2% | 91.8% | 92.6% |
| Ages 65+ | 12,954 | 52.0% | 50.8% | 53.1% | 6,746 | 50.5% | 48.8% | 52.1% | 6,208 | 53.5% | 51.9% | 55.2% |

| Hodgkin Lymphoma | | | | | | | | | | | | |
|------------------|-----------------|-------------------|---------|---------|-------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | Black | | | | | | | |
| | | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 9,967 | 81.2% | 80.2% | 82.1% | 5,406 | 77.4% | 76.1% | 78.7% | 4,561 | 85.6% | 84.3% | 86.8% |
| Ages <45 | 6,544 | 87.0% | 86.0% | 87.9% | 3,477 | 83.4% | 81.9% | 84.8% | 3,067 | 91.0% | 89.8% | 92.1% |
| Ages 45-54 | 1,611 | 77.8% | 75.2% | 80.1% | 976 | 73.2% | 69.8% | 76.4% | 635 | 84.6% | 80.9% | 87.7% |
| Ages 55-64 | 990 | 67.1% | 63.3% | 70.6% | 559 | 60.7% | 55.4% | 65.5% | 431 | 75.4% | 69.8% | 80.1% |
| Ages 65-74 | 515 | 62.3% | 56.4% | 67.6% | 259 | 60.3% | 51.7% | 67.9% | 256 | 64.3% | 56.0% | 71.5% |
| Ages 75+ | 308 | 43.5% | 35.4% | 51.2% | 135 | 45.7% | 32.7% | 57.7% | 173 | 40.6% | 29.7% | 51.2% |
| Ages <65 | 9,144 | 83.3% | 82.4% | 84.2% | 5,012 | 79.0% | 77.6% | 80.3% | 4,132 | 88.5% | 87.3% | 89.6% |
| Ages 65+ | 823 | 55.8% | 50.9% | 60.4% | 394 | 56.5% | 49.0% | 63.2% | 429 | 55.2% | 48.6% | 61.3% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 22. Five-Year Relative Survival*, Non-Hodgkin Lymphoma, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Non-Hodgkin Lymphoma | | | | | | | | | | | | |
|----------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | All Races | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 561,950 | 67.6% | 67.4% | 67.8% | 301,557 | 65.7% | 65.5% | 65.9% | 260,393 | 69.8% | 69.6% | 70.0% |
| Ages <45 | 63,057 | 79.0% | 78.7% | 79.4% | 38,337 | 76.4% | 76.0% | 76.9% | 24,720 | 83.1% | 82.6% | 83.6% |
| Ages 45-54 | 72,974 | 77.6% | 77.3% | 77.9% | 42,169 | 74.2% | 73.7% | 74.7% | 30,805 | 82.2% | 81.7% | 82.7% |
| Ages 55-64 | 112,393 | 74.7% | 74.4% | 75.0% | 62,704 | 71.4% | 71.0% | 71.9% | 49,689 | 78.7% | 78.3% | 79.2% |
| Ages 65-74 | 136,006 | 68.0% | 67.6% | 68.3% | 73,056 | 65.0% | 64.6% | 65.5% | 62,950 | 71.2% | 70.8% | 71.7% |
| Ages 75+ | 179,521 | 53.1% | 52.7% | 53.5% | 86,396 | 50.8% | 50.2% | 51.4% | 93,125 | 55.1% | 54.6% | 55.6% |
| Ages <65 | 247,780 | 76.7% | 76.5% | 76.9% | 142,856 | 73.7% | 73.4% | 74.0% | 104,924 | 80.8% | 80.6% | 81.1% |
| Ages 65+ | 314,860 | 59.8% | 59.5% | 60.0% | 159,098 | 57.6% | 57.2% | 58.0% | 155,762 | 61.8% | 61.5% | 62.2% |

| Non-Hodgkin Lymphoma | | | | | | | | | | | | |
|----------------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | White | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 492,298 | 67.9% | 67.7% | 68.1% | 264,584 | 66.1% | 65.8% | 66.3% | 227,714 | 70.0% | 69.7% | 70.2% |
| Ages <45 | 47,701 | 81.5% | 81.2% | 81.9% | 29,415 | 78.7% | 78.2% | 79.2% | 18,286 | 86.1% | 85.5% | 86.6% |
| Ages 45-54 | 60,041 | 79.4% | 79.1% | 79.8% | 34,878 | 76.3% | 75.8% | 76.9% | 25,163 | 83.7% | 83.2% | 84.2% |
| Ages 55-64 | 97,345 | 75.6% | 75.2% | 75.9% | 54,595 | 72.5% | 72.0% | 72.9% | 42,750 | 79.5% | 79.0% | 80.0% |
| Ages 65-74 | 122,205 | 68.4% | 68.0% | 68.7% | 66,021 | 65.5% | 65.0% | 65.9% | 56,184 | 71.7% | 71.2% | 72.2% |
| Ages 75+ | 166,806 | 53.2% | 52.8% | 53.6% | 80,673 | 50.8% | 50.2% | 51.4% | 86,133 | 55.3% | 54.8% | 55.8% |
| Ages <65 | 204,527 | 78.2% | 78.0% | 78.4% | 118,575 | 75.3% | 75.0% | 75.6% | 85,952 | 82.2% | 81.9% | 82.5% |
| Ages 65+ | 288,402 | 59.9% | 59.6% | 60.1% | 146,370 | 57.7% | 57.3% | 58.1% | 142,032 | 62.0% | 61.6% | 62.4% |

| Non-Hodgkin Lymphoma | | | | | | | | | | | | |
|----------------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Black | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 45,627 | 61.4% | 60.8% | 62.0% | 24,161 | 58.0% | 57.2% | 58.7% | 21,466 | 65.3% | 64.5% | 66.1% |
| Ages <45 | 11,009 | 65.6% | 64.6% | 66.6% | 6,410 | 63.0% | 61.7% | 64.3% | 4,599 | 69.2% | 67.8% | 70.7% |
| Ages 45-54 | 9,249 | 63.7% | 62.5% | 64.8% | 5,295 | 57.8% | 56.2% | 59.3% | 3,954 | 71.6% | 70.0% | 73.2% |
| Ages 55-64 | 9,861 | 63.8% | 62.6% | 65.0% | 5,351 | 58.6% | 57.0% | 60.3% | 4,510 | 70.0% | 68.3% | 71.6% |
| Ages 65-74 | 8,403 | 60.1% | 58.7% | 61.5% | 4,164 | 55.8% | 53.7% | 57.9% | 4,239 | 64.2% | 62.2% | 66.0% |
| Ages 75+ | 7,243 | 48.1% | 46.2% | 49.9% | 3,011 | 46.2% | 43.1% | 49.2% | 4,232 | 49.4% | 47.0% | 51.7% |
| Ages <65 | 30,051 | 64.5% | 63.9% | 65.2% | 17,025 | 60.2% | 59.3% | 61.0% | 13,026 | 70.3% | 69.4% | 71.2% |
| Ages 65+ | 15,612 | 54.7% | 53.6% | 55.9% | 7,157 | 51.9% | 50.2% | 53.6% | 8,455 | 57.0% | 55.5% | 58.5% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 23. Five-Year Relative Survival*, Myeloma, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Myeloma | | | | | | | | | | | | |
|------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | All Races | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 179,670 | 44.6% | 44.3% | 44.9% | 98,069 | 44.9% | 44.4% | 45.3% | 81,601 | 44.4% | 43.9% | 44.8% |
| Ages <45 | 6,345 | 69.2% | 67.8% | 70.5% | 3,738 | 67.9% | 66.1% | 69.6% | 2,607 | 71.0% | 69.0% | 73.0% |
| Ages 45-54 | 20,079 | 60.8% | 60.0% | 61.6% | 11,330 | 58.6% | 57.5% | 59.7% | 8,749 | 63.7% | 62.5% | 64.9% |
| Ages 55-64 | 39,795 | 54.9% | 54.3% | 55.6% | 22,638 | 54.8% | 54.0% | 55.6% | 17,157 | 55.1% | 54.2% | 56.1% |
| Ages 65-74 | 50,973 | 44.2% | 43.6% | 44.8% | 28,635 | 43.5% | 42.7% | 44.2% | 22,338 | 45.1% | 44.2% | 45.9% |
| Ages 75+ | 62,689 | 28.5% | 27.9% | 29.0% | 31,862 | 28.7% | 27.9% | 29.5% | 30,827 | 28.2% | 27.5% | 28.9% |
| Ages <65 | 66,133 | 58.2% | 57.7% | 58.7% | 37,650 | 57.3% | 56.7% | 57.9% | 28,483 | 59.4% | 58.7% | 60.0% |
| Ages 65+ | 113,611 | 35.9% | 35.5% | 36.3% | 60,471 | 36.1% | 35.6% | 36.7% | 53,140 | 35.6% | 35.1% | 36.2% |

| Myeloma | | | | | | | | | | | | |
|------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | White | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 137,044 | 43.7% | 43.3% | 44.0% | 77,034 | 44.4% | 43.9% | 44.9% | 60,010 | 42.8% | 42.2% | 43.3% |
| Ages <45 | 4,061 | 69.0% | 67.3% | 70.6% | 2,555 | 68.6% | 66.4% | 70.6% | 1,506 | 69.7% | 66.9% | 72.2% |
| Ages 45-54 | 13,697 | 62.4% | 61.5% | 63.4% | 8,090 | 60.6% | 59.3% | 61.8% | 5,607 | 65.1% | 63.6% | 66.5% |
| Ages 55-64 | 28,659 | 55.1% | 54.4% | 55.8% | 16,905 | 55.1% | 54.1% | 56.0% | 11,754 | 55.2% | 54.1% | 56.3% |
| Ages 65-74 | 39,084 | 44.1% | 43.4% | 44.7% | 22,543 | 43.6% | 42.7% | 44.4% | 16,541 | 44.7% | 43.7% | 45.7% |
| Ages 75+ | 51,713 | 27.8% | 27.2% | 28.4% | 27,053 | 28.6% | 27.7% | 29.4% | 24,660 | 27.0% | 26.2% | 27.8% |
| Ages <65 | 46,353 | 58.6% | 58.1% | 59.2% | 27,505 | 58.1% | 57.3% | 58.8% | 18,848 | 59.4% | 58.6% | 60.3% |
| Ages 65+ | 90,752 | 35.2% | 34.8% | 35.6% | 49,572 | 35.8% | 35.2% | 36.4% | 41,180 | 34.5% | 33.8% | 35.1% |

| Myeloma | | | | | | | | | | | | |
|------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Black | | | | | | | | | | | |
| | Male and female | | | | Male | | | | Female | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 36,277 | 46.8% | 46.1% | 47.5% | 17,709 | 45.8% | 44.8% | 46.8% | 18,568 | 47.8% | 46.9% | 48.8% |
| Ages <45 | 1,942 | 68.2% | 65.7% | 70.6% | 978 | 64.8% | 61.1% | 68.2% | 964 | 71.7% | 68.2% | 74.9% |
| Ages 45-54 | 5,523 | 56.1% | 54.5% | 57.7% | 2,798 | 52.0% | 49.7% | 54.3% | 2,725 | 60.3% | 58.0% | 62.5% |
| Ages 55-64 | 9,553 | 53.3% | 52.0% | 54.6% | 4,897 | 53.0% | 51.2% | 54.8% | 4,656 | 53.6% | 51.8% | 55.4% |
| Ages 65-74 | 10,064 | 43.9% | 42.6% | 45.2% | 5,109 | 42.1% | 40.2% | 44.0% | 4,955 | 45.7% | 43.9% | 47.6% |
| Ages 75+ | 9,231 | 30.7% | 29.2% | 32.2% | 3,946 | 29.1% | 26.8% | 31.5% | 5,285 | 31.8% | 29.9% | 33.7% |
| Ages <65 | 16,998 | 56.0% | 55.1% | 56.9% | 8,663 | 54.0% | 52.7% | 55.3% | 8,335 | 58.0% | 56.7% | 59.3% |
| Ages 65+ | 19,290 | 37.9% | 36.9% | 38.9% | 9,053 | 36.8% | 35.4% | 38.3% | 10,237 | 38.8% | 37.5% | 40.2% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).

Table 24. Five-Year Relative Survival*, Leukemia, by Race, Sex, and Age Group — National Program of Cancer Registries[†], 2001-2013.

| Leukemia | | | | | | | | | | | | |
|------------|-----------------|-------------------|---------|---------|-----------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Male and female | | | | All Races | | | | Female | | | |
| | | | | | Male | | | | | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 370,329 | 53.8% | 53.6% | 54.0% | 212,941 | 54.2% | 53.9% | 54.5% | 157,388 | 53.2% | 52.9% | 53.5% |
| Ages <45 | 59,021 | 70.9% | 70.5% | 71.2% | 33,480 | 70.8% | 70.3% | 71.3% | 25,541 | 70.9% | 70.3% | 71.5% |
| Ages 45-54 | 38,130 | 65.9% | 65.3% | 66.4% | 22,316 | 67.8% | 67.1% | 68.5% | 15,814 | 63.1% | 62.3% | 63.9% |
| Ages 55-64 | 64,362 | 61.6% | 61.1% | 62.0% | 39,415 | 62.0% | 61.4% | 62.6% | 24,947 | 60.9% | 60.2% | 61.6% |
| Ages 65-74 | 84,183 | 51.3% | 50.9% | 51.8% | 50,950 | 50.7% | 50.1% | 51.3% | 33,233 | 52.2% | 51.6% | 52.9% |
| Ages 75+ | 124,995 | 37.1% | 36.6% | 37.5% | 67,016 | 36.2% | 35.7% | 36.8% | 57,979 | 37.9% | 37.3% | 38.5% |
| Ages <65 | 161,412 | 66.1% | 65.9% | 66.4% | 95,146 | 66.6% | 66.3% | 67.0% | 66,266 | 65.4% | 65.0% | 65.8% |
| Ages 65+ | 209,044 | 43.1% | 42.8% | 43.4% | 117,871 | 42.9% | 42.4% | 43.3% | 91,173 | 43.4% | 43.0% | 43.9% |

| Leukemia | | | | | | | | | | | | |
|------------|-----------------|-------------------|---------|---------|---------|-------------------|---------|---------|---------|-------------------|---------|---------|
| Age group | Male and female | | | | White | | | | Female | | | |
| | | | | | Male | | | | | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 323,547 | 53.7% | 53.5% | 54.0% | 187,397 | 54.1% | 53.8% | 54.4% | 136,150 | 53.3% | 52.9% | 53.6% |
| Ages <45 | 47,053 | 71.9% | 71.5% | 72.4% | 26,874 | 71.8% | 71.3% | 72.4% | 20,179 | 72.1% | 71.4% | 72.7% |
| Ages 45-54 | 31,717 | 67.0% | 66.4% | 67.6% | 18,676 | 69.0% | 68.2% | 69.7% | 13,041 | 64.2% | 63.2% | 65.1% |
| Ages 55-64 | 55,578 | 62.2% | 61.8% | 62.7% | 34,387 | 62.6% | 61.9% | 63.2% | 21,191 | 61.7% | 61.0% | 62.5% |
| Ages 65-74 | 74,698 | 51.7% | 51.2% | 52.1% | 45,621 | 50.9% | 50.3% | 51.5% | 29,077 | 52.8% | 52.1% | 53.5% |
| Ages 75+ | 114,825 | 37.3% | 36.9% | 37.7% | 62,052 | 36.4% | 35.8% | 37.0% | 52,773 | 38.3% | 37.7% | 38.9% |
| Ages <65 | 134,260 | 66.9% | 66.6% | 67.2% | 79,881 | 67.3% | 67.0% | 67.7% | 54,379 | 66.3% | 65.8% | 66.7% |
| Ages 65+ | 189,402 | 43.3% | 43.0% | 43.6% | 107,586 | 42.9% | 42.5% | 43.3% | 81,816 | 43.7% | 43.3% | 44.2% |

| Leukemia | | | | | | | | | | | | |
|------------|-----------------|-------------------|---------|---------|--------|-------------------|---------|---------|--------|-------------------|---------|---------|
| Age group | Male and female | | | | Black | | | | Female | | | |
| | | | | | Male | | | | | | | |
| | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI | N | Relative Survival | 95% LCI | 95% UCI |
| All Ages | 31,015 | 48.3% | 47.6% | 49.0% | 16,569 | 49.1% | 48.1% | 50.0% | 14,446 | 47.4% | 46.4% | 48.4% |
| Ages <45 | 7,422 | 61.7% | 60.5% | 62.9% | 4,072 | 61.5% | 59.9% | 63.1% | 3,350 | 61.9% | 60.1% | 63.6% |
| Ages 45-54 | 4,304 | 54.6% | 52.8% | 56.3% | 2,414 | 55.2% | 52.8% | 57.5% | 1,890 | 53.9% | 51.3% | 56.4% |
| Ages 55-64 | 5,916 | 50.8% | 49.3% | 52.4% | 3,297 | 51.2% | 49.1% | 53.4% | 2,619 | 50.3% | 48.0% | 52.6% |
| Ages 65-74 | 6,470 | 42.8% | 41.3% | 44.4% | 3,601 | 42.1% | 39.9% | 44.3% | 2,869 | 43.7% | 41.4% | 46.0% |
| Ages 75+ | 6,936 | 29.4% | 27.8% | 31.1% | 3,205 | 29.6% | 27.1% | 32.2% | 3,731 | 29.2% | 27.0% | 31.4% |
| Ages <65 | 17,629 | 56.5% | 55.7% | 57.4% | 9,774 | 56.7% | 55.6% | 57.9% | 7,855 | 56.3% | 55.0% | 57.5% |
| Ages 65+ | 13,396 | 36.2% | 35.0% | 37.3% | 6,800 | 36.5% | 34.9% | 38.2% | 6,596 | 35.8% | 34.2% | 37.4% |

Abbreviations: LCI = Lower confidence interval; UCI = Upper confidence interval.

*Based on cases diagnosed between 2001-2013 and follow-up of patients through 2013.

[†]Data compiled from 34 cancer registries (AL, AK, AZ, CA, CO, DE, FL, GA, ID, IL, IN, KS, KY, LA, ME, MD, MI, MN, MS, MO, NE, NH, NJ, NY, NC, ND, OR, PA, RI, SC, VT, WV, WI, and WY) that met the data quality criteria for survival analysis (covering approximately 67% of the U.S. population), as submitted to CDC's National Program of Cancer Registries (NPCR) in November 2016. For more information see USCS technical notes (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/relative_survival/).